Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS
         Jan 25
NEWS
                 FSTA has been reloaded and moves to weekly updates
         Jan 29
NEWS 4
                 DKILIT now produced by FIZ Karlsruhe and has a new update
         Feb 01
                  frequency
NEWS 5
         Feb 19
                 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
                 Gene Names now available in BIOSIS
NEWS
         Mar 08
      7
         Mar 22
                 TOXLIT no longer available
NEWS
NEWS 8
         Mar 22
                 TRCTHERMO no longer available
NEWS 9
         Mar 28
                 US Provisional Priorities searched with P in CA/CAplus
                  and USPATFULL
NEWS 10
         Mar 28
                 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11
                 PAPERCHEM no longer available on STN. Use PAPERCHEM2
         Apr 02
instead.
NEWS 12
         Apr 08
                  "Ask CAS" for self-help around the clock
NEWS 13
         Apr 09
                 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14
         Apr 09
                 ZDB will be removed from STN
NEWS 15
         Apr 19
                 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 16
         Apr 22
                 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 17
         Apr 22
                 BIOSIS Gene Names now available in TOXCENTER
NEWS 18
         Apr 22
                 Federal Research in Progress (FEDRIP) now available
NEWS 19
         Jun 03
                 New e-mail delivery for search results now available
NEWS 20
         Jun 10
                 MEDLINE Reload
NEWS 21
         Jun 10
                 PCTFULL has been reloaded
NEWS EXPRESS
              February 1 CURRENT WINDOWS VERSION IS V6.0d,
              CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
              AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:56:50 ON 26 JUN 2002

=> fil reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:57:03 ON 26 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 25 JUN 2002 HIGHEST RN 433682-07-6 DICTIONARY FILE UPDATES: 25 JUN 2002 HIGHEST RN 433682-07-6

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\STNEXP4\QUERIES\09763216.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d 11

L1 HAS NO ANSWERS

L1

STR

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:57:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 219 TO ITERATE

100.0% PROCESSED 219 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3493 TO 5267 PROJECTED ANSWERS: 672 TO 1568

L3 50 SEA SSS SAM L1

=> d scan

L3 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 2-Furancarboxamide, N-[[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)

MF C43 H55 F3 N4 O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 2-Furancarboxamide, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)

MF C28 H36 N2 O3

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 50 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 2-Furancarboxamide, 5-[(3,4-dihydro-4,4,7-trimethyl-2H-1-benzopyran-6-yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI)

MF C27 H31 N O6

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s 11 ful

FULL SEARCH INITIATED 09:58:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4278 TO ITERATE

100.0% PROCESSED 4278 ITERATIONS SEARCH TIME: 00.00.01

994 ANSWERS

SEARCH TIME. 00.00.01

L4 994 SEA SSS FUL L1

=> fil caplus COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 140.66 140.87

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:58:28 ON 26 JUN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2002 VOL 136 ISS 26 FILE LAST UPDATED: 24 Jun 2002 (20020624/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 14 L5

26 L4

=> d ibib abs hitstr 1-YOU HAVE REQUESTED DATA FROM 26 ANSWERS - CONTINUE? Y/(N):y

AS ANSWER 1 OF 26 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2002:136881 CAPLUS

ACCESSION NUMBER: 2002:136881 CAPLUS
TITLE: A preliminary study on polyhydrazides incorporating

furan moieties

AUTHOR(S): Afli, Aljia; Gharbi, Souhir; El Gharbi, Rachid; Le

Bigot, Yves; Gandini, Alessandro

CORPORATE SOURCE: Laboratoire de Synthese et Physicochimie Organique,

Faculte des Sciences, Universite de Sfax, Sfax, 3038,

Tunisia

SOURCE: European Polymer Journal (2002), 38(4), 667-673

CODEN: EUPJAG; ISSN: 0014-3057

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Soln. and interfacial polycondensation of difurance dihydrazides with arom. or aliph. dicarboxylic acid dichlorides led to the corresponding

polyhydrazides which were characterized in terms of structure and av. chain length. Their conversion to the corresponding polyoxadiazoles was also examd. Model compds. were prepd. to facilitate the synthesis and

the

characterization of the polymers.

IT 433246-73-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (monomer; polyhydrazides incorporating furan moieties)

RN 433246-73-2 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-(1-phenylethylidene)bis-, dihydrazide (9CI) (CA INDEX NAME)

REFERENCE COUNT:

10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR

THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2001:904102 CAPLUS

DOCUMENT NUMBER: 136:37614

TITLE: Preparation of chiral

heterocyclylcarbonylaminobicyclo

heptanehydrocarboncarboxylic acids in remedy composition antagonistic to both PGD2 and TXA2

receptors

INVENTOR(S): Tanimoto, Norihiko; Arimura, Akinori

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	ND	DATE			A	PPLI	CATI	ON NO	ο.	DATE						
							_									
WO 2001094309		A1		20011213			WO 2001-JP4430 20010528									
W: AE	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
. CO	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	
HR	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	
LU	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,	RU,	
SD	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UŻ,	VN,	
YU	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM					
RW: GH	GM,	ΚE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	
DE	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	
BJ	CF,	CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG			

PRIORITY APPLN. INFO.:

JP 2000-166305 A 20000602

OTHER SOURCE(S):

MARPAT 136:37614

Ι

GΙ

AB Title compds. [I; A = alkylene optionally having an unsatd. bond; R = COR1, CH2OCH3, CH2OH; R1 = OH, OCH3, NH2, NHSO2CH3; X1, X3 independently

optionally substituted aryl, optionally substituted heteroaryl; X2 = single bond, CH2, S, SO2, CH2O, OCH2, CH2S, SCH2; Y = bicycloheptane] and pharmaceutically acceptable salts or solvates, having antagonistic effect on both thromboxane A2 and prostaglandin D2 receptors, are prepd. Thus, the title compd. II was prepd. and biol. tested for TXA2 receptor antagonistic activity with IC50(.mu.M) = 0.011 and PGD2 receptor antagonistic activity with IC50(.mu.M) = 0.079.

IT 291745-46-5P 291745-47-6P 291747-03-0P 291747-04-1P

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of chiral

heterocyclylcarbonylaminobicycloheptanehydrocarboncar

boxylic acids in remedy compn. as PGD2 and TXA2 receptors antagonists)

RN 291745-46-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

RN 291745-47-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

RN 291747-03-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

291747-04-1 CAPLUS RN

5-Heptenoic acid, 7-[(1R, 2R, 3S, 5S)-6, 6-dimethyl-2-[[[5-(phenylmethyl)-2-([18-(phenCN furanyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ANSWER 3 OF 26 CAPLUS COPYRIGHT 2002 ACS 2001:617978 CAPLUS

2

ACCESSION NUMBER:

135:195564

DOCUMENT NUMBER: TITLE:

Preparation of phenoxyalkylamine derivatives useful

as

opioid .delta. receptor agonists

INVENTOR(S):

Tsushima, Masaki; Tadauchi, Kaori; Asai, Kenji;

Miike,

Naoko; Imai, Masako; Kudo, Toshiaki

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan

SOURCE:

PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent Japanese

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND DATE					A:	PPLI	CATI	и ис	Э.	DATE				
WO	2001060796			A1		2001	0823		W	20	01-J	P111	- <b>-</b> 6	20010216				
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	ΓI,	GB,	GD,	GE,	GH,	GM,	HR,	
		HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	
		LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	
		SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	ΤZ,	UA,	UG,	US,	UZ,	VN,	YU,	
		ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM						
	RW:	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	
		ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
PRIORITY	APP	LN.	INFO	. :		JP 2000-40791 A 20000								218				

OTHER SOURCE(S):

MARPAT 135:195564

GΙ

$$X-A-B \xrightarrow{R^2} O \xrightarrow{R^3} R^4$$

$$C \xrightarrow{R^2} C \xrightarrow{R^3} R^5$$

$$R \xrightarrow{R^4} R^5$$

$$R \xrightarrow{R^5} R^5$$

AB The title compds. I [X is a group represented by the general formula R7R8NCO, etc.; A is a satd. or unsatd. 3- to 6-membered carbocyclic group or the like; B is CH2 or the like; n is 0 to 2; R1 is hydrogen, halogeno, or the like; R2, R3, and R7, R8 are each hydrogen, optionally substituted lower alkyl, or the like; R4 is hydrogen, optionally substituted lower alkyl, or the like; R5 is hydrogen, halogeno, or the like; and R6 is a satd. or unsatd. mono- or bicyclic carbocyclic group or the like, or alternatively, R5 and R6, R7 and R8 may be united to form a cyclic structure] are prepd. In an in vitro test for affinity for the .delta. opioid receptors,

IT 356072-04-3P 356072-05-4P 356072-06-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenoxyalkylamine derivs. useful as opioid .delta. receptor agonists)

RN 356072-04-3 CAPLUS

CN 2-Furancarboxamide,

5-[[2-[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethoxy]phenyl]methyl]-N,N-diethyl-(9CI) (CA INDEX NAME)

RN 356072-05-4 CAPLUS

CN 2-Furancarboxamide, N, N-diethyl-5-[[2-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 356072-06-5 CAPLUS

CN 2-Furancarboxamide, N,N-diethyl-5-[[2-[2-[4-[2-(hydroxymethyl)-1H-benzimidazol-1-yl]-1-piperidinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

IT 356073-29-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of phenoxyalkylamine derivs. useful as opioid .delta. receptor
 agonists)

RN 356073-29-5 CAPLUS

CN 2-Furancarboxamide, N,N-diethyl-5-[[2-(2-oxoethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THIS

THERE ARE 20 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

**FORMAT** 

ANSWER 4 OF 26 CAPLUS COPYRIGHT 2002 ACS

20

ACCESSION NUMBER: DOCUMENT NUMBER:

2000:824211 CAPLUS 134:4764

TITLE:

Preparation of 3-(benzoylamino)propionic acid

derivatives as glucagon antagonists/inverse agonists Ling, Anthony; Plewe, Michael Bruno; Truesdale, Larry Kenneth; Lau, Jesper; Madsen, Peter; Sams, Christian; Behrens, Carsten; Vagner, Josef; Christensen, Inge

Thoger; Lundt, Behrend Frederik; Sidelmann, Ulla

Grove; Thogersen, Henning

PATENT ASSIGNEE(S):

Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.

PCT Int. Appl., 564 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

INVENTOR(S):

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATE	PATENT NO.				KIND DATE				APPLI	CATI	٥.	DATE					
WO 20	0000698	A.	1	20001123			WO 2000-DK264 20000516										
Ţ	W: AE, AG, AL,				AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	
	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	
	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	
	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX.	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	
				•	•				TZ,	•	•		•		•	•	
	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM	·	·		•				
I	RW: GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	
	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	
	CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG					
EP 13	EP 1183229			A1 20020306				I	EP 20	00-9	5	20000516					
I	R: AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
	IE,	SI,	LT,	LV,	FI,	RO											
BR 20	Ā	·	20020	0319		E	BR 20	00-1	0651		20000516						
NO 20		20020	0117		NO 2001-5607												
PRIORITY A					DK 1	1999-	684		Α	1999	0517						
									DK 2000-478 A								
							1	WO 2	2000-1	DK26	4	W	2000	0516			
OTHER SOUR	RCE(S):			MARPAT 134:4764													

上(5)

GI

$$V^{A} Y^{Z} V^{A} Y^{D} I CH_{2} V$$

AB The title compds. [I; V = CO2R2, CONR2R3, CONR2OR3, etc. (wherein R2, R3

H, alkyl); A = (CH2)n(CR8R9)bNR7, (CR8R9)b(CH2)nNR7, (CR8R9)b(CH2)n, etc. (b = 0-1; n = 0-3; R7 = H, alkyl), (cycloalkyl)alkyl; R8, R9 = H, alkyl);

= CO, SO2, O, a bond; Z = (un)substituted phenylene, divalent radical derived from 5-6 membered heteroarom. ring contg. 1-2 heteroatoms selected

from N, O and S; or AYZ together = II; R1 = H, alkyl; X = CO(CR13R14)r(CH2)s, SO2(CR13R14)r(CH2)s, CO2(CR13R14)r(CH2)s, etc. (r = 0-1; s = 0-3; R13, R14 = H, alkyl); D = (un)substituted Ph, pyridyl, cyclopropyl, etc.; E = (un)substituted quinolinyl, 2,5-dioxopiperidinyl, biphenylalkyl, etc.] which act to antagonize the action of the glucagon hormone on the glucagon receptor (data given), and therefore may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity, were prepd. and formulated. E.g., a multi-step solid phase synthesis of III was given. Compds. I are effective at 0.05-10 mg/kg/day.

## IT 307988-42-7P 307988-43-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

RN 307988-42-7 CAPLUS

Y

CN 2-Furancarboxylic acid, 5-[(2,4,6-trimethylphenyl)methyl]-,

2-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]methyl]-2-[cis-4-(1,1-dimethylethyl)cyclohexyl]hydrazide (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 307988-43-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[(2,4,6-trimethylphenyl)methyl]-, 2-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]methyl]-2-(4-cyclohexylphenyl)hydrazide (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O \\ C - NH - CH_2 - CH_2 - CO_2H \\ \hline \\ CH_2 & O \\ N - NH - C \\ \hline \\ Me \\ Me \\ \end{array}$$

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ANSWER 5 OF 26 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:645983 CAPLUS

3

DOCUMENT NUMBER: 133:222579

TITLE: Preparation of [2.2.1] and [3.1.1]bicycloheptane

antagonistic to both of PGD2/TXA2 receptors

INVENTOR(S): Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura,

Akinori

PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan

SOURCE: PCT Int. Appl., 251 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE: Patent Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ----------WO 2000053573 Α1 20000914 WO 2000-JP1223 20000302 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1176139 A1 20020130 EP 2000-906622 20000302 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO PRIORITY APPLN. INFO.: JP 1999-62721 A 19990310 WO 2000-JP1223 W 20000302 OTHER SOURCE(S): MARPAT 133:222579 GI

$$(CH_2) m-NHCO-x1$$
 $(x^4) p$ 
 $x^2$ 
 $x^3$ 

$$Q = Q^1 = Me$$
 $Q^2 = Me$ 
 $Q^2 = Me$ 

AB Medicinal compns. contg. the title compds. [I; ring Y = Q, Q1, Q2; R1 = CH2CH:CH(CH2)3CO2R2, CH:CH(CH2)3CO2R2; wherein R2 = H, alkyl; m = 0,1; p = 0,1; when p = 0, X1 and X3 are not linked to each other through X4; X1, X3 = (un)substituted aryl or heteroaryl; X2 = CH2, CH2CH2, CO, O, S, SO, SO2,

Ι

NH, NHMe, C(:NOMe), N:N, CH:CH, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2; X4 = CH2, CH2CH2, CO, SO, SO2, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2], prodrugs or pharmaceutically acceptable salts thereof, or hydrate thereof antagonistic to both of thromboxane A2 and prostaglandin D2 receptors and medicinal compns. for the treatment of asthma and nasal obstruction are claimed. Thus, (5Z)-7-[(1R,2S,3S,4S)-3-aminobicyclo[2.2.1]hept-2-yl]-5-heptenoic acid Me ester was condensed

with

5-(pyrrole-1-sulfonyl)thiophene-2-carboxylic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole in THF under ice-cooling at 25.degree. for 16 h, followed by sapon. with a mixt. of 4 N aq. NaOH and THF and acidification with 5 N aq. HCl to give title compd. [II; R = 5-(pyrrole-1-sulfonyl)thiophene-2-carbonyl] (III). III and II [R = 2-(thiophen-2-ylthiomethyl)thiophen-5-yl] showed IC50 of 0.0043 and 0.001 .mu.M, resp., for inhibiting the binding the [3H](+)-(5Z)-7-[3-endo-(phenylsulfonylamino)bicyclo[2.2.1]hept-2-exo-yl]heptenoic acid sodium salt to prostaglandin D2 receptor prepn. from human peripheral blood platelet.

IT 291745-46-5P 291745-47-6P 291747-03-0P 291747-04-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [2.2.1] and [3.1.1] bicycloheptane as antagonists of PGD2/TXA2 receptors for treatment of asthma and nasal obstruction)

RN 291745-46-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

RN 291745-47-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

09763216.trn \* Page 17

Double bond geometry as shown.

RN 291747-03-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

RN 291747-04-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

Me R H N Ph 
$$\mathbb{Z}$$
 (CH2) 3  $\mathbb{Z}$  CO2H

RECORD. ALL CITATIONS AVAILABLE IN THE RE **FORMAT** ANSWER 6 OF 26 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:241135 CAPLUS DOCUMENT NUMBER: 132:279106 TITLE: Non-peptide GnRH agents, methods and intermediates

REFERENCE COUNT:

for

GI

their preparation

INVENTOR(S):

Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins,

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

Eileen Valenzuela; Li, Haitao; Faust, James Agouron Pharmaceuticals, Inc., USA; et al.

PATENT ASSIGNEE(S): SOURCE:

PCT Int. Appl., 444 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.					KIND				I	APPLI	CATI	ON NO	DATE					
	WO 2000020358								7		99-U		19990820					
WC	2000	0203	58	A	3	2000	1116											
	W:	ΑE,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	, BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	
		DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	, GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	
		JP,	KE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	, LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	
		MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	, RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ;	
		TM,	TR,	TT,	UA,	UG,	US,	UZ,	VN,	, YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	KZ,	
		MD,	RU,	ТJ,	TM													
	RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SL,	SZ,	, UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	
		ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	, MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	
		CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	, SN,	TD,	TG						
BF	9913	374		Α		2001	0515		BR 1999-13374 19990820									
EF	1105	120		A2 20010613					EP 1999-968010 19990820									
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FΙ,	RO											
NC	2001	0003	09	Α		2001	0411		NO 2001-309 ·					20010119				
	1273	_				2002								20010316				
LI	4904			В		2002	0425		I	T 20	01-2	4		2001	0319			
PRIORIT	Y APP	LN.	INFO	. :					US 1	1998-	9752	0 P	P	19980	0820			
								1	WO 1	1999-	US18	790	W	19990	0820			
OTHER S	OURCE	(S):			MAR	PAT	132:2	2791	06									

Hong Liu

$$R^{5}$$
  $R^{1}$   $R^{2}$ 

Het-X

 $R^{7}$ 
 $R^{8}$ 
 $R^{9}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 

AB Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. The compds. and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and

steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compds. include those of formula I [X = C:O, C:S, S:O, or SO2; Het = 5-membered NOS-heterocycle; R1, R2 = H, alkyl; R3-R7 = H, halo, (un) substituted alkyl, aryl, heteroaryl, CH2OR, OR, CO2R; R = alkyl, aryl, etc.; adjacent rings positions such as R6R7 may form (un) substituted 5- or 6-membered ring with up to 4 heteroatoms; R8 = lipophilic moiety such as alkyl,

II

aryl,

CH2OR, OR, etc.; R9 = H, (un)substituted alkyl]. Methods and intermediates for synthesizing the compds. are also described. For instance, 4,4,7-trimethylchroman (prepn. given) was alkylated in the 6-and 8-positions using Et 5-(chloromethyl)-2-furoate (46% total yield),

the resulting esters were hydrolyzed to a mixt. of acids. This unsepd. mixt. was treated with SOC12 and amidated with

2,4,6-trimethoxyphenylamine-

and

HCl to give the invention compd. II and its chroman-6-position isomer, which were sepd. by HPLC. Several compds. exhibited high affinity (<100 nM) at human GnRH receptors. The compds. antagonized GnRH-stimulated inositol phosphate accumulation in cells with recombinant human GnRH receptors, and an example compd. reduced plasma LH levels in castrated male rats. Various biol. data for several hundred compds. are given.

IT 263850-02-8P 263850-03-9P 263850-04-0P 263850-05-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
 (comparison compd.; prepn. of non-peptide GnRH agents for regulating
 gonadotropin secretion)

RN 263850-02-8 CAPLUS

CN 2-Furancarboxamide,

5-[hydroxy(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263850-03-9 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-04-0 CAPLUS

CN 2-Furancarboxamide, 5-[(3-chloro-6-methoxy-2,4-dimethylphenyl)methyl]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & MeO & Me\\ H_2N-C & O & CH_2 & C1\\ \hline \end{array}$$

RN 263850-05-1 CAPLUS

CN 2-Furancarboxylic acid, 5-[(4-hydroxy-2,5-dimethoxyphenyl)methyl]-,

4-[[5-[[4-[[5-[[(2,6-dimethoxyphenyl)amino]carbonyl]-2-furanyl]methyl]-2,5-dimethoxyphenoxy]carbonyl]-2-furanyl]methyl]-2,5-dimethoxyphenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

## IT 263878-35-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of non-peptide GnRH agents for regulating gonadotropin secretion)

RN 263878-35-9 CAPLUS

CN 2-Furancarboxamide,

5-[(5,6,7,8-tetrahydro-3-methoxy-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

## IT 263848-89-1P 263849-96-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compd.; prepn. of non-peptide GnRH agents for regulating gonadotropin secretion)

RN 263848-89-1 CAPLUS

CN 2-Furancarboxamide, N-[[3-(aminomethyl)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$ 

RN 263849-96-3 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[[4-hydroxy-2-methyl-5-(1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

ΙT 263847-53-6P 263847-54-7P 263847-55-8P 263847-56-9P 263847-61-6P 263847-62-7P 263847-63-8P 263847-64-9P 263847-65-0P 263847-66-1P 263847-67-2P 263847-68-3P 263847-69-4P 263847-70-7P 263847-71-8P 263847-72-9P 263847-73-0P 263847-74-1P 263847-75-2P 263847-76-3P 263847-77-4P 263847-78-5P 263847-79-6P 263847-80-9P 263847-81-0P 263847-82-1P 263847-83-2P 263847-84-3P 263847-85-4P 263847-86-5P 263847-87-6P 263847-88-7P 263847-89-8P 263847-90-1P 263847-91-2P 263847-92-3P 263847-93-4P 263847-94-5P 263847-95-6P 263847-96-7P 263847-97-8P 263847-98-9P 263847-99-0P 263848-00-6P 263848-01-7P 263848-02-8P 263848-03-9P 263848-04-0P 263848-05-1P 263848-06-2P 263848-07-3P 263848-08-4P 263848-09-5P 263848-10-8P 263848-11-9P 263848-12-0P 263848-13-1P 263848-14-2P 263848-15-3P 263848-16-4P 263848-17-5P 263848-18-6P 263848-19-7P 263848-20-0P 263848-21-1P 263848-22-2P 263848-23-3P 263848-24-4P 263848-25-5P 263848-26-6P 263848-27-7P 263848-28-8P 263848-29-9P 263848-30-2P 263848-31-3P 263848-32-4P 263848-33-5P 263848-34-6P 263848-35-7P 263848-36-8P 263848-37-9P 263848-38-0P 263848-39-1P 263848-40-4P 263848-41-5P 263848-42-6P 263848-43-7P

```
263848-44-8P 263848-45-9P 263848-46-0P
    263848-47-1P 263848-48-2P 263848-49-3P
    263848-50-6P 263848-51-7P 263848-52-8P
    263848-53-9P 263848-54-0P 263848-55-1P
    263848-56-2P 263848-57-3P 263848-58-4P
    263848-59-5P 263848-60-8P 263848-61-9P
    263848-62-0P 263848-63-1P 263848-64-2P
    263848-65-3P 263848-66-4P 263848-67-5P
    263848-68-6P 263848-69-7P 263848-70-0P
    263848-71-1P 263848-72-2P 263848-73-3P
    263848-74-4P 263848-75-5P 263848-76-6P
    263848-77-7P 263848-78-8P 263848-79-9P
    263848-80-2P 263848-81-3P 263848-82-4P
    263848-83-5P 263848-84-6P 263848-85-7P
    263848-86-8P 263848-87-9P 263848-88-0P
    263848-90-4P 263848-91-5P 263848-92-6P
    263848-93-7P 263848-94-8P 263848-95-9P
    263848-97-1P 263848-98-2P 263848-99-3P
    263849-00-9P 263849-02-1P 263849-03-2P
    263849-04-3P 263849-05-4P 263849-06-5P
    263849-07-6P 263849-08-7P 263849-09-8P
    263849-10-1P 263849-11-2P 263849-12-3P
    263849-13-4P 263849-14-5P 263849-15-6P
    263849-16-7P 263849-17-8P 263849-18-9P
    263849-19-0P 263849-20-3P 263849-21-4P
    263849-22-5P 263849-23-6P 263849-24-7P
    263849-25-8P 263849-26-9P 263849-27-0P
    263849-28-1P 263849-29-2P 263849-30-5P
    263849-31-6P 263849-32-7P 263849-33-8P
    263849-34-9P 263849-35-0P 263849-36-1P
    263849-37-2P 263849-38-3P 263849-39-4P
    263849-40-7P 263849-41-8P 263849-42-9P
    263849-43-0P 263849-44-1P 263849-47-4P
    263849-49-6P 263849-51-0P 263849-53-2P
    263849-55-4P 263849-56-5P 263849-57-6P
    263849-58-7P 263849-59-8P 263849-60-1P
    263849-61-2P 263849-62-3P 263849-63-4P
    263849-64-5P 263849-65-6P 263849-66-7P
    263849-67-8P 263849-68-9P 263849-69-0P
    263849-70-3P 263849-71-4P 263849-73-6P
    263849-74-7P 263849-75-8P 263849-76-9P
    263849-78-1P 263849-79-2P 263849-80-5P
    263849-81-6P 263849-82-7P 263849-83-8P
    263849-84-9P 263849-85-0P 263849-86-1P
    263849-87-2P 263849-88-3P 263849-89-4P
    263849-90-7P 263849-91-8P 263849-92-9P
    263849-93-0P 263849-94-1P 263849-95-2P
    263849-97-4P 263850-00-6P 263850-01-7P
    263850-07-3P 263850-08-4P 263850-09-5P
    RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
    study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
    BIOL (Biological study); PREP (Preparation); USES (Uses)
        (target compd.; prepn. of non-peptide GnRH agents for regulating
       gonadotropin secretion)
```

RN 263847-53-6 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[[4-(2-methoxyethoxy)-2-methyl-5-(1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263847-54-7 CAPLUS

CN 2-Furancarboxamide, 5-[[2,4-dimethyl-5-(1-methylethenyl)phenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me} & \text{Me} & \text{O} & \text{MeO} & \text{OMe} \\ \text{Me} - \text{C} & \text{CH}_2 & \text{C} - \text{NH} & \text{OMe} \\ \\ \text{CH}_2 & \text{OMe} & \text{OMe} \end{array}$$

RN 263847-55-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263847-56-9 CAPLUS

CN 2-Furancarboxamide, 5-[[5-[1-[(ethylamino)carbonyl]cyclopropyl]-2-methylphenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263847-61-6 CAPLUS

CN 2-Furancarboxamide,

N-[[4-[[(aminoiminomethyl)amino]methyl]cyclohexyl]meth yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263847-62-7 CAPLUS

CN 2-Furancarboxamide,

N-[[trans-4-[[(aminoiminomethyl)amino]methyl]cyclohexy l]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263847-63-8 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]methyl]cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me CH2 
$$\sim$$
 CH2  $\sim$  CH2  $\sim$  NH  $\sim$  CH2  $\sim$  NH  $\sim$  Me Me Me

RN 263847-64-9 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263847-65-0 CAPLUS

CN 2-Furancarboxamide, N-[(5-methylpyrazinyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-66-1 CAPLUS

CN 2-Furancarboxamide, N-[(4-methylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-67-2 CAPLUS

CN 2-Furancarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-68-3 CAPLUS

CN 2-Furancarboxamide, N-[(4-cyanocyclohexyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me CH<sub>2</sub> 
$$CH_2$$
  $CH_2$   $CH$ 

RN 263847-69-4 CAPLUS

CN 2-Furancarboxamide,

N-[(2,3-dimethylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-70-7 CAPLUS

CN 2-Furancarboxamide,

N-[(3,4-dimethylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-71-8 CAPLUS

CN 2-Furancarboxamide, N-(3-acetylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-72-9 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-73-0 CAPLUS

CN 2-Furancarboxamide, N-[4-[(aminoiminomethyl)amino]butyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $O$   $C-NH-(CH_2)_4-NH-C-NH_2 Me Me Me$ 

RN 263847-74-1 CAPLUS
CN 2-Furancarboxamide,
N-[[3-[[(aminoiminomethyl)amino]methyl]cyclohexyl]meth
 yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl] (9CI) (CA INDEX NAME)

RN 263847-75-2 CAPLUS
CN 2-Furancarboxamide,
N-[[cis-4-[(aminoiminomethyl)amino]methyl]cyclohexyl]
 methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263847-78-5 CAPLUS
CN 2-Furancarboxamide, N-[5-[(diethylamino)sulfonyl]-2-methoxyphenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263847-79-6 CAPLUS

CN 2-Furancarboxamide, N,N'-1,3-propanediylbis[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 263847-80-9 CAPLUS

CN 2-Furancarboxamide, N,N'-1,6-hexanediylbis[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

Me Me 
$$CH_2$$
  $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$ 

PAGE 1-B

RN 263847-81-0 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

RN 263847-82-1 CAPLUS

CN 2-Furancarboxamide, N-[4-(4-morpholinyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-83-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263847-84-3 CAPLUS

CN Benzeneacetic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263847-85-4 CAPLUS

CN Benzeneacetic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2 - CO_2H$$

Me Me Me

RN 263847-86-5 CAPLUS

CN 2-Furancarboxamide,

N-[[trans-4-[[(aminoiminomethyl)amino]methyl]cyclohexy l]methyl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263847-87-6 CAPLUS

CN 2-Furancarboxamide, N-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263847-88-7 CAPLUS
CN 2-Furancarboxamide,
N-(cyclohexylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-89-8 CAPLUS
CN 2-Furancarboxamide,
N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-90-1 CAPLUS
CN Hexanoic acid, 6-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $O$   $C-NH-(CH_2)_5-C-OMe$  Me Me Me

RN 263847-91-2 CAPLUS

CN 2-Furancarboxamide, N-[(3-chlorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-92-3 CAPLUS

CN 2-Furancarboxamide, N-(2-methoxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263847-93-4 CAPLUS

CN 2-Furancarboxamide, N-[(3-methylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-94-5 CAPLUS

CN 2-Furancarboxamide, N-[(4-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-95-6 CAPLUS

CN 2-Furancarboxamide,

N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-96-7 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

RN 263847-97-8 CAPLUS

CN 2-Furancarboxamide, N-[(5-methylpyrazinyl)methyl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 263847-98-9 CAPLUS

CN 2-Furancarboxamide, N-[(2-fluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263847-99-0 CAPLUS

CN 2-Furancarboxamide, N-(2-phenoxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-00-6 CAPLUS

CN 2-Furancarboxamide,

N-(1H-benzimidazol-2-ylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-01-7 CAPLUS

CN 2-Furancarboxamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-02-8 CAPLUS

CN 2-Furancarboxamide, N-[(2-methylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-03-9 CAPLUS

CN 2-Furancarboxamide, N-[(2-chlorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-04-0 CAPLUS

CN 2-Furancarboxamide,

N-[(2,4-difluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263848-05-1 CAPLUS

CN 2-Furancarboxamide, N-[(3-fluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-06-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(3-fluorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-07-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-chlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-08-4 CAPLUS

CN 2-Furancarboxamide,

N-[(2,4-dimethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-09-5 CAPLUS

CN 2-Furancarboxamide, N-[[(2R)-tetrahydro-2-furanyl]methyl]-5-[(5,6,7,8-

tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-10-8 CAPLUS

CN 2-Furancarboxamide, N-[[(2S)-tetrahydro-2-furanyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-11-9 CAPLUS

CN 2-Furancarboxamide,

N-[[4-(phenylmethyl)-2-morpholinyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-12-0 CAPLUS

CN 2-Furancarboxamide, N-[(5-methylpyrazinyl)methyl]-5-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-13-1 CAPLUS

CN 2-Furancarboxamide, N-(2-methoxy-6-methylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-14-2 CAPLUS

CN 2-Furancarboxamide,

N-[2-[3,4-bis(phenylmethoxy)phenyl]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-15-3 CAPLUS

CN 2-Furancarboxamide, N-[2-[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-16-4 CAPLUS

CN 2-Furancarboxamide, N-5-quinolinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-17-5 CAPLUS

CN 2-Furancarboxamide, N-[2-[[[5-[(dimethylamino)methyl]-2-

furanyl]methyl]thio]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me 
$$CH_2 - CH_2 - S - CH_2 - CH_2 - S - CH_2 - CH_2 - S - CH_2 - CH_2 - CH_2 - S - CH_2 - CH_$$

RN 263848-18-6 CAPLUS

CN 2-Furancarboxamide,

N-([1,1'-biphenyl]-3-ylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263848-19-7 CAPLUS

CN 2-Furancarboxamide,

N-([1,1'-biphenyl]-2-ylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-20-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263848-21-1 CAPLUS

CN 2-Furancarboxamide, N-[4-[[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]butyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

Me Me 
$$CH_2$$
  $O$   $C-NH-(CH_2)_4-NH$   $NH-CH_2$   $Me$  Me Me

PAGE 1-B

RN 263848-22-2 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-

pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} CH_2 \\ NH \\ CH_2 \\ NH \\ Me \end{array}$$

RN 263848-23-3 CAPLUS

CN 2-Furancarboxamide,

N-[[4-[[(4,6-dimethoxy-2-pyrimidinyl)amino]methyl]cycl ohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-24-4 CAPLUS

CN Benzoic acid,

4-methoxy-3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA

INDEX NAME)

RN 263848-25-5 CAPLUS

CN 2-Furancarboxamide, N-(2-methylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-26-6 CAPLUS

CN 2-Furancarboxamide,

RN 263848-27-7 CAPLUS

CN 2-Furancarboxamide, N-[[4-(aminomethyl)cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-28-8 CAPLUS

CN 2-Furancarboxamide, N-(4-piperidinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-29-9 CAPLUS

CN 2-Furancarboxamide, 5-[(2,5-dimethylphenyl)methyl]-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} Me \\ \hline \\ CH_2 \\ \hline \\ Me \\ \end{array}$$

RN 263848-30-2 CAPLUS

CN 2-Furancarboxamide, N-3-pyridinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-31-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-

RN 263848-32-4 CAPLUS

CN 2-Furancarboxamide, 5-[(3-bromo-2,4,6-trimethylphenyl)methyl]-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-33-5 CAPLUS

CN 2-Furancarboxamide, N-[(5-methylpyrazinyl)methyl]-5-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me} & \text{O} & \text{O} \\ \text{CH}_2 & \text{O} & \text{C-NH-CH}_2 & \text{N} \\ \text{Me} & \text{Me} & \text{Me} \end{array}$$

RN 263848-34-6 CAPLUS

CN 2-Furancarboxamide, N-3-pyrrolidinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-35-7 CAPLUS

CN 2-Furancarboxamide, N-[3-(4-morpholinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C-NH-(CH_2)_3$   $N$   $Me$  Me Me Me

RN 263848-36-8 CAPLUS

CN 2-Furancarboxamide, 5-[(4,5-dimethoxy-2-methylphenyl)methyl]-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} \\ \text{MeO} \\ \hline \\ \text{CH}_2 \\ \hline \\ \text{O} \\ \text{C}-\text{NH}-\text{CH}_2 \\ \hline \\ \text{N} \\ \hline \\ \text{Me} \\ \end{array}$$

RN 263848-37-9 CAPLUS

CN 2-Furancarboxamide,

N-[[trans-4-(1H-benzimidazol-2-yl)cyclohexyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

RN 263848-38-0 CAPLUS

CN 2-Furancarboxamide,

N-(2,6-diethylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-39-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 263848-40-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 263848-41-5 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-

Hong Liu

Me Me Me CH<sub>2</sub> 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263848-42-6 CAPLUS

CN 2-Furancarboxamide,

N-[[4-[[[(3,5-dimethyl-4-isoxazolyl)methyl]amino]methy l]cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-43-7 CAPLUS

CN 2-Furancarboxamide, N-[[4-[[(1,2,3,6-tetrahydro-2,6-dioxo-4-

pyrimidinyl)methyl]amino]methyl]cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-B

 $\approx_0$ 

RN 263848-44-8 CAPLUS

CN 2-Furancarboxamide, N-[[4-[[(4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]methyl]cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-45-9 CAPLUS

CN 2-Furancarboxamide,

N-[[4-[[(4-chloro-2-pyrimidinyl)amino]methyl]cyclohexy l]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-46-0 CAPLUS

CN 2-Furancarboxamide, N-[[4-[[(4-amino-5-cyano-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263848-47-1 CAPLUS

CN 2-Furancarboxamide, N-(1-naphthalenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-48-2 CAPLUS

CN 2-Furancarboxamide, N-(1H-indol-5-ylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $CH_2$   $NH$ 

RN 263848-49-3 CAPLUS

CN 2-Furancarboxamide,

N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phen yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263848-50-6 CAPLUS

CN 2-Furancarboxamide, N-(2,5-dimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-51-7 CAPLUS

CN 2-Furancarboxamide, N-(2,4-dimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-52-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 263848-53-9 CAPLUS

CN Carbamic acid, [4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 263848-54-0 CAPLUS

CN 2-Furancarboxamide, N-[4-(aminocarbonyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-55-1 CAPLUS

CN 2-Furancarboxamide,

N-[[1-(2-chloro-4-pyrimidinyl)-4-piperidinyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263848-56-2 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-

Me Me Me 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263848-57-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-

naphthalenyl)methyl]-N-[[3-[[(trifluoroacetyl)amino]methyl]cyclohexyl]meth
yl]- (9CI) (CA INDEX NAME)

Me Me Me CH<sub>2</sub> 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263848-58-4 CAPLUS

CN 2-Furancarboxamide, N-[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263848-60-8 CAPLUS

CN 2-Furancarboxamide, N-1H-indazol-5-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-61-9 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[4-[(trifluoroacetyl)amino]cyclohexyl]- (9CI) (CAINDEX NAME)

Me Me Me 
$$CH_2$$

O  $CH_2$ 

NH-  $C-CF_3$ 

Me Me Me

RN 263848-62-0 CAPLUS

CN 2-Furancarboxamide,

N-[[4-[(2-pyrimidinylamino)methyl]cyclohexyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263848-63-1 CAPLUS

CN 2-Furancarboxamide,

N-(4-aminocyclohexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263848-64-2 CAPLUS

CN 2-Furancarboxamide, N-[[4-(aminomethyl)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-65-3 CAPLUS
CN 2-Furancarboxamide,
N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263848-66-4 CAPLUS
CN 2-Furancarboxamide,
N-[4-(aminoiminomethyl)phenyl]-5-[(5,6,7,8-tetrahydro3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-67-5 CAPLUS CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-

Me Me CH2 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263848-68-6 CAPLUS

CN 2-Furancarboxamide, N-[1-[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-

pyrimidinyl]-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-69-7 CAPLUS

CN Benzoic acid, 3,4,5-trimethoxy-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263848-70-0 CAPLUS

CN Boronic acid, [3-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

RN 263848-71-1 CAPLUS

CN 2-Furancarboxylic acid, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-,

[3-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 263848-72-2 CAPLUS

CN 2-Furancarboxamide, N-[3-(hydroxymethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-73-3 CAPLUS

CN 2-Furancarboxamide, N-(3-methoxypropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-

pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-NH-(CH_2)_3-OMe$  Me Me Me

RN 263848-74-4 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-1-(4-methylphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-75-5 CAPLUS

CN 2-Furancarboxamide, N-[(2S)-2-hydroxy-2-phenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-76-6 CAPLUS

CN 2-Furancarboxamide, N-(4,4-dimethoxybutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-77-7 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-78-8 CAPLUS

CN 2-Furancarboxamide, N-[[3-(aminomethyl)cyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-79-9 CAPLUS

CN 2-Furancarboxamide, N-[[1-[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]-4-piperidinyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-80-2 CAPLUS

CN 2-Furancarboxamide, N-[(4-methoxy-1-naphthalenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-81-3 CAPLUS

CN 2-Furancarboxamide, N-[(4-fluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-82-4 CAPLUS

CN 2-Furancarboxamide, N-(2,2-dimethoxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me O O OMe 
$$\parallel$$
 C-NH-CH<sub>2</sub>-CH-OMe Me Me Me

RN 263848-83-5 CAPLUS

CN 2-Furancarboxamide, N-(2-propoxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263848-84-6 CAPLUS

CN 2-Furancarboxamide,

N-[2-(1,3-dioxolan-2-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-85-7 CAPLUS

CN Benzoic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $C-O-CH_2-CH_2-NEt_2$ 

Me Me Me

RN 263848-86-8 CAPLUS

N 2-Furancarboxamide,

N-[[3-[[[2-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-

4-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-87-9 CAPLUS

CN 2-Furancarboxamide, N-[[4-[(2-pyrimidinylamino)methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-88-0 CAPLUS

CN 2-Furancarboxamide,

N-[[3-[(2-pyrimidinylamino)methyl]cyclohexyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263848-90-4 CAPLUS

CN 2-Furancarboxamide, 5-[(3-bromo-2,4,6-trimethylphenyl)methyl]-N-(2,6-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263848-91-5 CAPLUS

CN 2-Furancarboxamide, N-[[4-[[(4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-92-6 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[(5-methylthieno[2,3-d]pyrimidin-4-yl)amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-93-7 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[3-[[[4-(trifluoromethyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263848-94-8 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[(2-amino-6-methyl-4-pyrimidinyl)amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263848-95-9 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[(2-amino-6-chloro-4-pyrimidinyl)amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263848-97-1 CAPLUS
CN 2-Furancarboxamide,
N-[[3-[[[4-[[[(2R)-tetrahydro-2-furanyl]methyl]amino]-

2-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-98-2 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-

2-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263848-99-3 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[(7-methylthieno[3,2-d]pyrimidin-4-yl)amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-00-9 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[4-(4-morpholinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

$$-N$$

RN 263849-02-1 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[5-methyl-4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]methyl]phenyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263849-03-2 CAPLUS

CN 2-Furancarboxamide, N-[4-[[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-

pyrimidinyl]amino]cyclohexyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-04-3 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[4-[(3-methoxypropyl)amino]-2-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

Me Me CH2 CH2 NH CH2 NH NH

Me Me Me

PAGE 1-B

- (CH<sub>2</sub>)<sub>3</sub>-OMe

RN 263849-05-4 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[2-[(2-methoxyethyl)amino]-4-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-B

- CH $_2$ - CH $_2$ - OMe

RN 263849-06-5 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[[imino[[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]amino]methyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-B

$$-NH-CH_2$$

RN 263849-07-6 CAPLUS

CN 2-Furancarboxamide, N-[[trans-4-(aminocarbonyl)cyclohexyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

RN 263849-08-7 CAPLUS

CN 2-Furancarboxamide, N-[[3-[[(4-amino-5-fluoro-2-pyrimidinyl)amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-09-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-methyl-2-[[[3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-B

— ОМе

RN 263849-10-1 CAPLUS

CN 2-Furancarboxamide,

N-[4-(hydroxymethyl)-2,6-dimethoxyphenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-11-2 CAPLUS

CN 2-Furancarboxamide, N-(2-methoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-12-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(methylthio)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-13-4 CAPLUS

CN Glycine, N-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-NH-CH_2-CO_2H$  Me Me Me

RN 263849-14-5 CAPLUS

CN 2-Furancarboxamide,

N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-15-6 CAPLUS

CN Glycine, N-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $C$ 

RN 263849-16-7 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-17-8 CAPLUS

CN 2-Furancarboxamide, N-[[4-[(dimethylamino)methyl]phenyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263849-18-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(methylamino)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-19-0 CAPLUS

CN 2-Furancarboxamide, N-(2,4,6-trimethoxyphenyl)-5-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-20-3 CAPLUS

CN 2-Furancarboxamide, N-(5-acetyl-2,4-dimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX

NAME)

RN 263849-21-4 CAPLUS

CN 2-Furancarboxamide, 5-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-(1-methylethyl)-2-naphthalenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI)

(CA INDEX NAME)

RN 263849-22-5 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-23-6 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dimethoxy-2,6-dinitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-24-7 CAPLUS

CN 2-Furancarboxamide, N-[[trans-4-[[[2-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-4-pyrimidinyl]amino]methyl]cyclohexyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 263849-25-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-.alpha.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263849-26-9 CAPLUS

CN 2-Furancarboxamide, N-(3-cyano-2,4,6-trimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-27-0 CAPLUS

CN 2-Furancarboxamide, N-[[trans-4-[[[2-[[(2R)-tetrahydro-2-furanyl]methyl]amino]-4-pyrimidinyl]amino]methyl]cyclohexyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 263849-28-1 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-29-2 CAPLUS

CN 2-Furancarboxamide, N-[[3-[(1H-pyrrolo[2,3-d]pyrimidin-4-

ylamino)methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-30-5 CAPLUS
CN 2-Furancarboxamide,
N-(1H-benzimidazol-2-ylmethyl)-5-[(5,6,7,8-tetrahydro3-methoxy-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-31-6 CAPLUS
CN 2-Furancarboxamide,
5-[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-32-7 CAPLUS
CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,8,8-trimethyl-2-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-33-8 CAPLUS
CN 2-Furancarboxamide,
5-[(2,2,5,7,8-pentamethyl-2H-1-benzopy

5-[(2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)methyl]-N-(2,4,6-trimethoxyphenyl)-(9CI) (CA INDEX NAME)

RN 263849-34-9 CAPLUS

CN 2-Furancarboxamide, N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-35-0 CAPLUS

CN 2-Furancarboxamide, 5-[(2,5-dimethoxyphenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-36-1 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 3,4-dihydro-6-methoxy-4,4-dimethyl-8-[[5-[[(2,4,6-trimethoxyphenyl)amino]carbonyl]-2-furanyl]methyl]-, ethyl ester

## (9CI) (CA INDEX NAME)

RN 263849-37-2 CAPLUS

CN 2-Furancarboxamide, 5-[(3,4-dihydro-4,4,7-trimethyl-2H-1-benzopyran-8-yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-38-3 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dihydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-39-4 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-40-7 CAPLUS

CN 2-Furancarboxamide, N-(5,7-dimethyl-1,8-naphthyridin-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-41-8 CAPLUS

CN 2-Furancarboxamide, N-(2-ethoxy-6-hydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-42-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-, 3-hydroxy-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]phenyl ester (9CI) (CA INDEX NAME)

RN 263849-43-0 CAPLUS

CN 2-Furancarboxamide, N-(2,6-diethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-44-1 CAPLUS

CN 2-Furancarboxamide,

N-phenyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-47-4 CAPLUS

CN 2-Furancarboxamide, 5-[(pentamethylphenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-49-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-propyl-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263849-51-0 CAPLUS

CN 2-Furancarboxamide,

N-[[3-[[2-[[(2R)-tetrahydro-2-furanyl]methyl]amino]-

4-pyrimidinyl]amino]methyl]phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3-methoxy-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263849-53-2 CAPLUS

CN 2-Furancarboxamide, 5-[[5-(1,1-dimethylethyl)-2-methylphenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-55-4 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dichloro-4-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-56-5 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-57-6 CAPLUS

CN 2-Furancarboxamide, 5-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-58-7 CAPLUS

CN 2-Furancarboxamide,

N-(2,6-dimethoxyphenyl)-5-[(pentamethylphenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263849-59-8 CAPLUS

CN 2-Furancarboxamide, N-(5-nitro-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-60-1 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[[5-(1,1-dimethylethyl)-2-

methylphenyl]methyl] - (9CI) (CA INDEX NAME)

RN 263849-61-2 CAPLUS
CN 2-Furancarboxamide,
5-[[5-(1,1-dimethylethyl)-2-methylphenyl]methyl]-N-1H indol-5-yl- (9CI) (CA INDEX NAME)

RN 263849-62-3 CAPLUS
CN 2-Furancarboxamide, N-(2,4,6-trimethoxyphenyl)-5-[(2,3,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-63-4 CAPLUS
CN 2-Furancarboxamide, N-(2,4,6-trimethoxyphenyl)-5-[(2,3,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-64-5 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,3,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-65-6 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,3,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-66-7 CAPLUS

CN 2-Furancarboxamide,

5-[[5-(1,1-dimethylethyl)-2-methylphenyl]methyl]-N-[[3-[[[2-[[[(2R)-tetrahydro-2-furanyl]methyl]amino]-4pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263849-67-8 CAPLUS CN 2-Furancarboxamide,

N-(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[2-[4-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 263849-68-9 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxyethyl)-N-(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2-CH_2-OH$$

$$CH_2 \longrightarrow CH_2-CH_2-OH$$

$$Me Me Me Me$$

RN 263849-69-0 CAPLUS

CN 2-Furancarboxamide, N-(2-methylpropyl)-N-(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-70-3 CAPLUS

CN Glycine, N-(2-pyridinylmethyl)-N-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]-, ethyl ester (9CI)

(CA INDEX NAME)

RN 263849-71-4 CAPLUS

CN 2-Furancarboxamide, N-(3-cyano-2,4,6-trimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3-methoxy-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-73-6 CAPLUS

CN 2-Furancarboxamide, N-(2,4,6-trimethoxyphenyl)-5-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-74-7 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-75-8 CAPLUS

CN 2-Furancarboxamide, 5-[(3,4-dihydro-4,4,7-trimethyl-2H-1-benzopyran-6-

yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-76-9 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-2-methoxy-5-oxo-1-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-78-1 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,3,5,6-tetramethylphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-79-2 CAPLUS

CN 2-Furancarboxamide, 5-[(4-bromo-2,3,5,6-tetramethylphenyl)methyl]-N-(2,6-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-80-5 CAPLUS

CN 2-Furancarboxamide, 5-[(4-hydroxy-2,5-dimethoxyphenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-81-6 CAPLUS

CN 2-Furancarboxamide,

N-[4-ethoxy-2-methoxy-6-[(methylsulfonyl)amino]phenyl]- 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI)

(CA INDEX NAME)

RN 263849-82-7 CAPLUS

CN 2-Furancarboxamide, 5-[[5-(2,2-dimethyl-1-oxopropyl)-2,4-dimethoxyphenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-83-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5-acetyl-2,4-dimethylphenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-84-9 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[5-(1,1-dimethylpropyl)-2-methoxyphenyl]methyl]-(9CI) (CA INDEX NAME)

RN 263849-85-0 CAPLUS

CN 2-Furancarboxamide, 5-[[5-(1,1-dimethylpropyl)-2-methoxyphenyl]methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-86-1 CAPLUS

CN 2-Furancarboxamide, 5-[(3-chloro-6-methoxy-2,4-dimethylphenyl)methyl]-N-(2,6-dimethoxyphenyl)-(9CI) (CA INDEX NAME)

RN 263849-87-2 CAPLUS

CN 2-Furancarboxamide,

RN 263849-88-3 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethoxyphenyl)-5-[(2,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-89-4 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dimethylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-90-7 CAPLUS

CN 2-Furancarboxamide,

5-[(3-chloro-6-methoxy-2,4-dimethylphenyl)methyl]-N-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me} & \text{OMe} & \text{O} \\ \text{Cl} & \text{CH}_2 & \text{O} & \text{C-NH} \\ \text{N} & \text{N} & \text{Me} \end{array}$$

RN 263849-91-8 CAPLUS

CN 2-Furancarboxamide, N,N-diethyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263849-92-9 CAPLUS

CN 2-Furancarboxamide, 5-[(3-chloro-6-methoxy-2,4-dimethylphenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-93-0 CAPLUS

CN 2-Furancarboxamide, 5-[(2,3-dihydro-1,1,3,3,6-pentamethyl-1H-inden-5-yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-94-1 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-95-2 CAPLUS

CN 2-Furancarboxamide,

5-[(4,6-dimethyl[1,1'-biphenyl]-3-yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263849-97-4 CAPLUS

CN 2-Furancarboxamide, 5-[(5-cyclohexyl-2-methylphenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263850-00-6 CAPLUS

CN 2-Furancarboxamide, 5-[(3,4-dihydro-4,4,6-trimethyl-2H-1-benzopyran-8-yl)methyl]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 263850-01-7 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 3,4-dihydro-6,8-dimethoxy-4,4-dimethyl-5-[[5-[[(2,4,6-trimethoxyphenyl)amino]carbonyl]-2-furanyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 263850-07-3 CAPLUS
CN 2-Furancarboxamide,
N-[4-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me Me 
$$CH_2 - CH_2 - NH - CH_2 - CH_2 - NEt_2$$
Me Me Me Me

RN 263850-08-4 CAPLUS

CN 2-Furancarboxamide, N-[4-(2-hydroxyethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-09-5 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)

IT 263850-10-8P 263850-11-9P 263850-12-0P 263850-13-1P 263850-14-2P 263850-15-3P 263850-16-4P 263850-17-5P 263850-18-6P 263850-19-7P 263850-20-0P 263850-21-1P 263850-22-2P 263850-23-3P 263850-24-4P 263850-25-5P 263850-26-6P 263850-27-7P 263850-28-8P 263850-29-9P 263850-30-2P 263850-31-3P 263850-32-4P 263850-33-5P 263850-34-6P 263850-35-7P 263850-36-8P 263850-37-9P 263850-38-0P 263850-39-1P 263850-40-4P 263850-41-5P 263850-42-6P 263850-43-7P 263850-44-8P 263850-45-9P 263850-46-0P 263850-47-1P 263850-48-2P 263850-49-3P 263850-50-6P 263850-51-7P 263850-52-8P 263850-53-9P 263850-54-0P

```
263850-55-1P 263850-56-2P 263850-57-3P
263850-58-4P 263850-59-5P 263850-60-8P
263850-61-9P 263850-62-0P 263850-63-1P
263850-64-2P 263850-65-3P 263850-66-4P
263850-67-5P 263850-68-6P 263850-69-7P
263850-70-0P 263850-71-1P 263850-72-2P
263850-73-3P 263850-74-4P 263850-75-5P
263850-76-6P 263850-77-7P 263850-78-8P
263850-79-9P 263850-80-2P 263850-81-3P
263850-82-4P 263850-83-5P 263850-84-6P
263850-85-7P 263850-86-8P 263850-87-9P
263850-88-0P 263850-89-1P 263850-90-4P
263850-91-5P 263850-92-6P 263850-93-7P
263850-94-8P 263850-95-9P 263850-96-0P
263850-97-1P 263850-98-2P 263850-99-3P
263851-00-9P 263851-01-0P 263851-03-2P
263851-04-3P 263851-05-4P 263851-06-5P
263851-07-6P 263851-08-7P 263851-09-8P
263851-10-1P 263851-11-2P 263851-12-3P
263851-13-4P 263851-15-6P 263851-16-7P
263851-17-8P 263851-18-9P 263851-19-0P
263851-20-3P 263851-21-4P 263851-22-5P
263851-23-6P 263851-24-7P 263851-25-8P
263851-26-9P 263851-27-0P 263851-28-1P
263851-29-2P 263851-30-5P 263851-31-6P
263851-32-7P 263851-33-8P 263851-34-9P
263851-35-0P 263851-36-1P 263851-37-2P
263851-38-3P 263851-39-4P 263851-40-7P
263851-41-8P 263851-42-9P 263851-43-0P
263851-44-1P 263851-45-2P 263851-46-3P
263851-47-4P 263851-48-5P 263851-49-6P
263851-50-9P 263851-51-0P 263851-52-1P
263851-54-3P 263851-55-4P 263851-56-5P
263851-57-6P 263851-61-2P 263851-62-3P
263851-63-4P 263851-65-6P 263851-66-7P
263851-67-8P 263851-71-4P 263851-72-5P
263851-73-6P 263851-74-7P 263851-75-8P
263851-78-1P 263851-80-5P 263851-81-6P
263851-82-7P 263851-83-8P 263851-84-9P
263851-85-0P 263851-86-1P 263851-87-2P
263851-88-3P 263851-90-7P 263851-92-9P
263851-94-1P 263851-95-2P 263851-98-5P
263852-00-2P 263852-01-3P 263852-04-6P
263852-05-7P 263852-06-8P 263852-07-9P
263852-08-0P 263852-09-1P 263852-12-6P
263852-13-7P 263852-14-8P 263852-16-0P
263852-17-1P 263852-18-2P 263852-19-3P
263852-20-6P 263852-21-7P 263852-22-8P
263852-24-0P 263852-25-1P 263852-26-2P
263852-27-3P 263852-28-4P 263852-30-8P
263852-31-9P 263852-32-0P 263852-33-1P
263852-34-2P 263852-35-3P 263852-37-5P
263852-38-6P 263852-39-7P 263852-40-0P
263852-43-3P 263852-44-4P 263852-45-5P
263852-46-6P 263852-48-8P 263852-49-9P
```

```
263852-50-2P 263852-51-3P 263852-52-4P
     263852-54-6P 263852-56-8P 263852-59-1P
     263852-60-4P 263852-61-5P 263852-66-0P
     263852-68-2P 263852-70-6P 263852-71-7P
     263852-72-8P 263852-73-9P 263852-74-0P
     263852-76-2P 263852-77-3P 263852-78-4P
     263852-79-5P 263852-80-8P 263852-82-0P
     263852-83-1P 263852-84-2P 263852-85-3P
     RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (target compd.; prepn. of non-peptide GnRH agents for regulating
        gonadotropin secretion)
RN
     263850-10-8 CAPLUS
CN
     2-Furancarboxamide, N-(6-methoxy-3-pyridinyl)-5-[(5,6,7,8-tetrahydro-
     3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)
```

RN 263850-11-9 CAPLUS

CN 2-Furancarboxamide, N-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-12-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-hydroxyethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-13-1 CAPLUS

CN 2-Furancarboxamide, N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-14-2 CAPLUS

CN 2-Furancarboxamide, N-(5-methyl-1-phenyl-1H-pyrazol-3-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-15-3 CAPLUS

CN 2-Furancarboxamide, N-(5-methyl-2-thiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-16-4 CAPLUS

CN 2-Furancarboxamide, N-[2-(hydroxymethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-17-5 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)

RN 263850-18-6 CAPLUS

CN 2-Furancarboxamide, N-[4-(dimethylamino)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-19-7 CAPLUS

CN 2-Furancarboxamide, N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-20-0 CAPLUS

CN 2-Furancarboxamide, N-(3-methoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-21-1 CAPLUS

CN 2-Furancarboxamide, N-(4-ethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-22-2 CAPLUS

CN 2-Furancarboxamide, N-[4-(hydroxymethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-23-3 CAPLUS

CN 2-Furancarboxamide, N-(4-hydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-24-4 CAPLUS

CN 2-Furancarboxamide, N-(8-hydroxy-5-quinolinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-25-5 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-26-6 CAPLUS

CN 2-Furancarboxamide,

N-(2-cyano-4,5-dimethoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-27-7 CAPLUS

CN 2-Furancarboxamide, N-[2-[[[3-(dimethylamino)-2,2-dimethylpropyl]amino]carbonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-28-8 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263850-29-9 CAPLUS

CN 2-Furancarboxamide, N-[4-(cyanomethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-30-2 CAPLUS

CN 2-Furancarboxamide, N-[2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263850-31-3 CAPLUS

CN 2-Furancarboxamide, N-[2-[(1-azabicyclo[2.2.2]oct-3-ylamino)carbonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-32-4 CAPLUS

CN 2-Furancarboxamide, N-(3-cyanophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-33-5 CAPLUS

CN 2-Furancarboxamide, N-[2-[[(3-pyridinylmethyl)amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263850-34-6 CAPLUS

CN 2-Furancarboxamide, N-1H-indol-5-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-35-7 CAPLUS

CN 2-Furancarboxamide, N-1-isoquinolinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-36-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

RN 263850-37-9 CAPLUS

CN 2-Furancarboxamide, N-(2-methyl-5-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-38-0 CAPLUS

CN 2-Furancarboxamide, N-(3-methylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-39-1 CAPLUS

CN 2-Furancarboxamide, N-1H-indazol-6-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-40-4 CAPLUS

CN 2-Furancarboxamide, N-[4-(methylthio)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-41-5 CAPLUS

CN 2-Furancarboxamide, N-1,3-benzodioxol-5-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-NH$   $C-NH$ 

RN 263850-42-6 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl] phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-43-7 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxy-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-44-8 CAPLUS

CN 2-Furancarboxamide, N-(3-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-45-9 CAPLUS

CN 2-Furancarboxamide, N-(4-hydroxy-3-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-46-0 CAPLUS

CN 2-Furancarboxamide, N-[5-(hydroxymethyl)-2-methylphenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-47-1 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxy-6-methylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-48-2 CAPLUS

CN Benzoic acid,

2-methoxy-4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI)

(CA

INDEX NAME)

RN 263850-49-3 CAPLUS

CN 2-Furancarboxamide, N-(3-ethyl-6-methyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-50-6 CAPLUS

CN 2-Furancarboxamide, N-(4-hydroxy-2,3-dimethylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-51-7 CAPLUS

CN 2-Furancarboxamide, N-(1,4-dihydro-1,4-dioxo-6-phthalazinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-52-8 CAPLUS

CN 2-Furancarboxamide, N-(3-methyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-53-9 CAPLUS

CN 2-Furancarboxamide, N-(3-chloro-4-hydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-54-0 CAPLUS

CN 2-Furancarboxamide, N-(3-fluoro-4-methoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-55-1 CAPLUS

CN 2-Furancarboxamide, N-(1,2,3,4-tetrahydro-1,4-dioxo-5-phthalazinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-56-2 CAPLUS CN 2-Furancarboxamide,

N-[2-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phen yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263850-58-4 CAPLUS

CN 2-Furancarboxamide, N-[2-methyl-6-(1-methylethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-59-5 CAPLUS

CN 2-Furancarboxamide,

N-[2,4-dichloro-6-(trifluoromethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me C1 
$$CH_2$$
  $O$   $C-NH$   $C1$   $Me$  Me Me

RN 263850-60-8 CAPLUS

CN 2-Furancarboxamide, N-(4-acetylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-61-9 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dimethylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-62-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-methylethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-63-1 CAPLUS

CN 2-Furancarboxamide, N-(2-ethyl-6-methylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-64-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-hydroxyethoxy)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263850-65-3 CAPLUS

CN 2-Furancarboxamide,

N-(2-hydroxy-1,2-diphenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-66-4 CAPLUS

CN 2-Furancarboxamide, N-[(2-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-67-5 CAPLUS

CN 2-Furancarboxamide, N-(2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263850-68-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(phenylamino)ethyl]-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263850-69-7 CAPLUS

CN 2-Furancarboxamide, N-(2-furanylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-70-0 CAPLUS

CN 2-Furancarboxamide, N-[(4-chlorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-71-1 CAPLUS

CN 2-Furancarboxamide,

N-[(3,4-dimethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-72-2 CAPLUS

CN 2-Furancarboxamide, N-[(2-ethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-73-3 CAPLUS

CN 2-Furancarboxamide,

N-[(2,3-dichlorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-74-4 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-methoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-75-5 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)-2-phenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2$$
—OH  $CH_2$ —OH  $CH_2$ —OH  $CH_2$ —Ph Me Me Me

RN 263850-76-6 CAPLUS

CN 2-Furancarboxamide, N-[[2-(hydroxymethyl)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-77-7 CAPLUS

CN 2-Furancarboxamide, N-(1-methyl-3-phenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-78-8 CAPLUS

CN 2-Furancarboxamide, N-[3-(2-oxo-1-pyrrolidinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-79-9 CAPLUS

CN 2-Furancarboxamide,

RN 263850-80-2 CAPLUS

CN 2-Furancarboxamide, N-(1-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-81-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-82-4 CAPLUS

CN 2-Furancarboxamide, N-[2-(3,5-dimethoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-83-5 CAPLUS

CN 2-Furancarboxamide, N-cyclopropyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-84-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-methoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-85-7 CAPLUS

CN 2-Furancarboxamide, N-(2-cyanoethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263850-86-8 CAPLUS

CN 2-Furancarboxamide, N-[(3-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-87-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-methylphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-88-0 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxy-2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-89-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-fluorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-90-4 CAPLUS

CN 2-Furancarboxamide, N-[[4-(dimethylamino)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-91-5 CAPLUS

CN 2-Furancarboxamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-92-6 CAPLUS

CN 2-Furancarboxamide, N-[(2-bromophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-93-7 CAPLUS

CN 2-Furancarboxamide, N-[(3-nitrophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-94-8 CAPLUS

CN 2-Furancarboxamide,

N-(cyanophenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-95-9 CAPLUS

CN 2-Furancarboxamide, N-[(4-bromophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-96-0 CAPLUS

CN 2-Furancarboxamide, N-[(3-bromophenyl)methyl]-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-97-1 CAPLUS

CN 2-Furancarboxamide, N-[1-(4-nitrophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-98-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263850-99-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(3-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-00-9 CAPLUS

CN L-Arginine, N2-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263851-01-0 CAPLUS

CN 2-Furancarboxamide,

N-[3-(methylphenylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-03-2 CAPLUS

CN 2-Furancarboxamide, N-[2-[(4-nitrophenyl)amino]-2-oxoethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-04-3 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[2-(4-morpholinyl)ethyl]amino]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-05-4 CAPLUS

CN 2-Furancarboxamide, N-[2-[[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-

pyrimidinyl]amino]cyclohexyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-06-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-07-6 CAPLUS

CN 2-Furancarboxamide,

N-[3-(1H-imidazol-1-yl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me CH<sub>2</sub> O 
$$\parallel$$
 C-NH-(CH<sub>2</sub>)<sub>3</sub> N N Me Me Me

RN 263851-08-7 CAPLUS

CN 2-Furancarboxamide, N-(3-phenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $C-NH-(CH_2)_3-Ph$ 

Me Me Me

RN 263851-09-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(1H-indol-3-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-10-1 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

RN 263851-11-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-methoxyphenyl)-2-oxoethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX

NAME)

RN 263851-12-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(acetylamino)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-13-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]-(9CI)

(CA INDEX NAME)

RN 263851-15-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-nitrophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me NO2
$$CH_2 \longrightarrow CH_2 \longrightarrow CH_2$$

RN 263851-16-7 CAPLUS

CN 2-Furancarboxamide,

N-(1,3-benzodioxol-5-ylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-17-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-18-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-piperidinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-19-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-20-3 CAPLUS

CN 2-Furancarboxamide,

N-[(3,5-dimethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-21-4 CAPLUS

CN 2-Furancarboxamide, N-[3-(2-methyl-1-piperidinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-NH-(CH_2)_3$   $N$  Me Me Me Me

RN 263851-22-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(3-methoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-23-6 CAPLUS

CN Benzoic acid, 4-[[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-24-7 CAPLUS

CN 2-Furancarboxamide, N-[3-(methylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263851-25-8 CAPLUS

CN 2-Furancarboxamide,

N-(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-26-9 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-27-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(3-phenoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-28-1 CAPLUS

CN 2-Furancarboxamide, N-[3-(1-piperidinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-29-2 CAPLUS

CN 2-Furancarboxamide,

N-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-30-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-31-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(2,5-dimethoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-32-7 CAPLUS

CN 2-Furancarboxamide, N-[2-(5-chloro-1H-indol-3-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-33-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl) = N-(2,2,2-trifluoroethyl) - (9CI) (CA INDEX NAME)

RN 263851-34-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-phenoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263851-35-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(1H-imidazol-4-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-36-1 CAPLUS

CN 2-Furancarboxamide, N-[2-[[4-[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-

naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

Me Me 
$$CH_2$$
  $CH_2$   $NH-CH_2-CH_2-NH$   $NH-CH_2$   $NH-CH_2$   $NH-CH_2$ 

PAGE 1-B

RN 263851-37-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-38-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263851-39-4 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)-1H-purin-6-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-40-7 CAPLUS

CN 2-Furancarboxamide, N-(4-dibenzofuranylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-41-8 CAPLUS

CN 2-Furancarboxamide,

N-[(3,4-difluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-42-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-oxo-1-imidazolidinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-43-0 CAPLUS

CN 2-Furancarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-44-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-morpholinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-45-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-46-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[2-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

RN 263851-47-4 CAPLUS

CN 2-Furancarboxamide, N-[2-[[2-(1-pyrrolidinyl)ethyl]amino]ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263851-48-5 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxypropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-49-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(diethylamino)ethyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O Me 
$$| | | |$$
 CH2 CH2 CH2 NEt2 Me Me Me

RN 263851-50-9 CAPLUS

CN 2-Furancarboxamide,

N-(1,1-dimethylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-51-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-morpholinyl)ethyl]-N-(phenylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263851-52-1 CAPLUS

CN Glycine,

N-(phenylmethyl)-N-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263851-54-3 CAPLUS

CN 2-Furancarboxamide, N,N-di-2-propenyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me O 
$$CH_2-CH$$
  $CH_2$   $CH_2$ 

RN 263851-55-4 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-(2-hydroxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-56-5 CAPLUS

CN 2-Furancarboxamide, N-(phenylmethyl)-N-[2-(1-pyrrolidinyl)ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263851-57-6 CAPLUS

CN 2-Furancarboxamide, N-(2-cyanoethyl)-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2-CH_2-CN$$

$$CH_2 \longrightarrow CH_2$$
Me Me Me

RN 263851-61-2 CAPLUS

CN 2-Furancarboxamide,

N-(1-cyclohexylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-62-3 CAPLUS

CN 2-Furancarboxamide, N-[[4-(1-methylethyl)phenyl]methyl]-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $CH_2$ 

Pr-i

Me Me Me

RN 263851-63-4 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-(1-methyl-4-piperidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-65-6 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)cyclopentyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-66-7 CAPLUS

CN 2-Furancarboxamide,

N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]-(9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $CF_3$   $CF_3$ 

RN 263851-67-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-methyl-5-nitro-1H-pyrrol-1-yl)ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263851-71-4 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxypropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O O OH 
$$C-NH-CH_2-CH-Me$$
 Me Me Me

RN 263851-72-5 CAPLUS

CN 2-Furancarboxamide, N-(2-methoxy-1-methylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-73-6 CAPLUS

CN 2-Furancarboxamide, N-[2-cyclohexyl-1-(hydroxymethyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-74-7 CAPLUS

CN 2-Furancarboxamide, N-(2-cyanoethyl)-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-75-8 CAPLUS

CN 2-Furancarboxamide, N-[3-(1-methylethoxy)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-78-1 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263851-80-5 CAPLUS

CN 2-Furancarboxamide, N-[[(1R,2S)-2-hydroxycyclohexyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263851-81-6 CAPLUS

CN 2-Furancarboxamide, N-[[2,5-dimethyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-82-7 CAPLUS

CN 2-Furancarboxamide, N-(2-methylbutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-83-8 CAPLUS

CN 2-Furancarboxamide, N-9H-fluoren-9-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-84-9 CAPLUS

CN 2-Furancarboxamide,

N-[(1-hydroxycyclohexyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-85-0 CAPLUS

CN 2-Furancarboxamide, N-cyclobutyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-86-1 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)-2-methylpropyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-87-2 CAPLUS

CN 2-Furancarboxamide,

N-[2-(dimethylamino)ethyl]-N-(1-naphthalenylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me O 
$$CH_2$$
 O  $C-N-CH_2-CH_2-NMe_2$  Me Me

RN 263851-88-3 CAPLUS

CN 2-Furancarboxamide, N-(1,3-dioxolan-2-ylmethyl)-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-90-7 CAPLUS

CN 2-Furancarboxamide, N-[cyclopropyl(4-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-92-9 CAPLUS

CN 2-Furancarboxamide,

N-methyl-N-2-propynyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263851-94-1 CAPLUS

CN 2-Furancarboxamide, N-[(4-fluorophenyl)methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263851-95-2 CAPLUS

CN 2-Furancarboxamide, N, N-bis(2-methylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263851-98-5 CAPLUS

CN 2-Furancarboxamide,

N-(1,5-dimethylhexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 O Me  $CH_2$   $CH_$ 

RN 263852-00-2 CAPLUS

CN 2-Furancarboxamide, N-[(4-nitrophenyl)methyl]-N-propyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-01-3 CAPLUS

CN 2-Furancarboxamide,

 $N-[2-(dimethylamino)ethyl]-N-[(2-nitrophenyl)methyl]-5-\\ [(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)$ 

RN 263852-04-6 CAPLUS

CN 2-Furancarboxamide, N-(5-hydroxypentyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-05-7 CAPLUS

CN 2-Furancarboxamide,

N-[2-(1-cyclohexen-1-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-06-8 CAPLUS

CN 2-Furancarboxamide,

N-(phenylmethyl)-N-[2-(2-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2$$
— Ph  $CH_2$ —  $C$ 

RN 263852-07-9 CAPLUS

CN 2-Furancarboxamide, N-(2-phenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-08-0 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-09-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-N-(2-naphthalenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263852-12-6 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxy-2,2-dimethylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-13-7 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-naphthalenylamino)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-14-8 CAPLUS

CN 2-Furancarboxamide, N-(phenylmethyl)-N-[2-(1-piperidinyl)ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me O 
$$CH_2$$
— Ph  $CH_2$ —  $C$ 

RN 263852-16-0 CAPLUS

CN 2-Furancarboxamide, N-(2-furanylmethyl)-N-(1-methyl-2,5-dioxo-3-pyrrolidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-17-1 CAPLUS

CN 2-Furancarboxamide, N-[3-(dimethylamino)propyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX

NAME)

RN 263852-18-2 CAPLUS

CN 2-Furancarboxamide, N-(2-mercaptoethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-19-3 CAPLUS

CN 2-Furancarboxamide, N,N-bis(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-20-6 CAPLUS

CN 2-Furancarboxamide,

N-(2,2-dimethoxyethyl)-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263852-21-7 CAPLUS

CN 2-Furancarboxamide, N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$ 

RN 263852-22-8 CAPLUS CN 2-Furancarboxamide,

N-[[3-[[(1-oxo-2,3-diphenylpropyl)amino]methyl]phenyl] methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

Me Me Me O O O Ph O Ph O Ph O CH2 NH-CH2 
$$CH_2$$
  $CH_2$   $C$ 

PAGE 1-B

--- Ph

RN 263852-24-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(diethylamino)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-25-1 CAPLUS

CN 2-Furancarboxamide, N-(6-hydroxyhexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-26-2 CAPLUS

CN 2-Furancarboxamide, N-(3-furanylmethyl)-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-27-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(1,3-dioxolan-2-yl)ethyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-28-4 CAPLUS

CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-30-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-phenoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-31-9 CAPLUS

CN 2-Furancarboxamide, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O

 $CH_2$ 

O

 $CH_2$ 

N

Me

 $Me$ 
 $Me$ 
 $Me$ 

RN 263852-32-0 CAPLUS

CN 2-Furancarboxamide, N-(2-methyl-2-propenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263852-33-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)-1-methylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 O Me  $C-NH-CH-CH_2-NMe_2$  Me Me Me

RN 263852-34-2 CAPLUS

CN 2-Furancarboxamide, N-(tetrahydro-1,1-dioxido-3-thienyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-35-3 CAPLUS

CN 2-Furancarboxamide, N-[6-(dimethylamino)hexyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $C-NH-(CH_2)_6-NMe_2$ 
Me Me Me

RN 263852-37-5 CAPLUS

CN 2-Furancarboxamide, N-(1-methylethyl)-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $CH_2$ 

Ph

 $CH_2$ 

Me Me Me

RN 263852-38-6 CAPLUS

CN 2-Furancarboxamide,

N-(3,3-diphenylpropyl)-N-(2-furanylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-39-7 CAPLUS

CN 2-Furancarboxamide, N-(1-naphthalenylmethyl)-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-40-0 CAPLUS CN 2-Furancarboxamide,

N-(2-hydroxy-1,1-dimethylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-43-3 CAPLUS

CN 2-Furancarboxamide, N-(2-cyanoethyl)-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-44-4 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-1-phenylethyl]-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263852-45-5 CAPLUS

CN 2-Furancarboxamide, N-[[4-(1-methylethyl)phenyl]methyl]-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-46-6 CAPLUS

CN 2-Furancarboxamide, N-[3-(methylthio)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-NH-(CH_2)_3-SMe$  Me Me Me

RN 263852-48-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-chlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-49-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(3-bromo-4-methoxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-50-2 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-[(4-methylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-51-3 CAPLUS

CN 2-Furancarboxamide, N-(3,3-diphenylpropyl)-N-(2-pyridinylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263852-52-4 CAPLUS

CN 2-Furancarboxamide, N-[(2-cyanophenyl)methyl]-N-(1,2-diethyl-4-pyrazolidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-54-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(methylthio)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-56-8 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxycyclohexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-59-1 CAPLUS

CN 2-Furancarboxamide, N-(1,2-diethyl-4-pyrazolidinyl)-N-[[4-

(dimethylamino)phenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-60-4 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)

RN 263852-61-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(ethylthio)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-66-0 CAPLUS

CN 2-Furancarboxamide, N-(1,2-diethyl-4-pyrazolidinyl)-N-(7-hydroxy-3,7-dimethyloctyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me OH 
$$|$$
 CH2-CH2-CH-(CH2)3-C-Me Me Me Me Me Et

RN 263852-68-2 CAPLUS

CN 2-Furancarboxamide,

N-(2,2-dimethoxy-1-methylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263852-70-6 CAPLUS

CN 2-Furancarboxamide,

N-cyclohexyl-N-ethyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-71-7 CAPLUS

CN 2-Furancarboxamide,

N-(2-furanylmethyl)-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $CH_2$ 

O  $CH_2$ 

Me Me Me

RN 263852-72-8 CAPLUS

CN 2-Furancarboxamide, N-(1-ethylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-73-9 CAPLUS

CN 2-Furancarboxamide, N-(3-furanylmethyl)-N-(2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-74-0 CAPLUS

CN 2-Furancarboxamide, N-(1,2-diethyl-4-pyrazolidinyl)-N-(3-phenylbutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-76-2 CAPLUS

CN 2-Furancarboxamide, N-(3-methylbutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-77-3 CAPLUS

CN 2-Furancarboxamide,

N, N-bis(2-cyanoethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-78-4 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)butyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-79-5 CAPLUS

CN 2-Furancarboxamide, N-[(2-methoxyphenyl)methyl]-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-80-8 CAPLUS

CN 2-Furancarboxamide,

N-[1-(hydroxymethyl)-3-(methylthio)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-82-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-83-1 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxybutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263852-84-2 CAPLUS

CN 2-Furancarboxamide, N-butyl-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-85-3 CAPLUS

CN 2-Furancarboxamide, N-(2-furanylmethyl)-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

IT 263852-86-4P 263852-87-5P 263852-88-6P 263852-90-0P 263852-91-1P 263852-92-2P 263852-93-3P 263852-94-4P 263852-95-5P 263852-98-8P 263852-99-9P 263853-00-5P 263853-02-7P 263853-03-8P 263853-06-1P 263853-08-3P 263853-09-4P 263853-10-7P 263853-11-8P 263853-13-0P 263853-14-1P 263853-16-3P 263853-17-4P 263853-18-5P 263853-19-6P 263853-20-9P 263853-22-1P 263853-23-2P 263853-24-3P 263853-26-5P 263853-27-6P 263853-28-7P 263853-29-8P 263853-33-4P 263853-34-5P 263853-35-6P 263853-38-9P 263853-39-0P 263853-40-3P 263853-43-6P 263853-45-8P 263853-46-9P 263853-51-6P 263853-52-7P 263853-55-0P 263853-56-1P 263853-57-2P 263853-58-3P 263853-59-4P 263853-60-7P 263853-62-9P 263853-63-0P 263853-64-1P 263853-65-2P 263853-67-4P 263853-68-5P 263853-70-9P 263853-71-0P 263853-73-2P 263853-78-7P 263853-79-8P 263853-80-1P 263853-81-2P 263853-82-3P 263853-86-7P 263853-87-8P 263853-88-9P 263853-91-4P 263853-92-5P 263853-93-6P 263853-95-8P 263853-97-0P 263853-98-1P 263854-00-8P 263854-01-9P 263854-02-0P 263854-04-2P 263854-06-4P 263854-09-7P 263854-11-1P 263854-12-2P 263854-13-3P 263854-15-5P 263854-16-6P 263854-20-2P 263854-21-3P 263854-25-7P 263854-60-0P 263854-61-1P 263854-62-2P 263854-63-3P 263854-64-4P 263854-65-5P 263854-66-6P 263854-67-7P 263854-68-8P 263854-69-9P 263854-70-2P 263854-71-3P 263854-72-4P 263854-73-5P 263854-74-6P 263854-75-7P 263854-76-8P 263854-77-9P 263854-78-0P 263854-79-1P 263854-80-4P 263854-81-5P 263854-82-6P 263854-83-7P 263854-84-8P 263854-85-9P 263854-86-0P 263854-87-1P 263854-88-2P 263854-89-3P 263854-91-7P 263854-92-8P 263854-93-9P 263854-94-0P 263854-95-1P 263854-96-2P 263854-97-3P 263854-98-4P 263854-99-5P 263855-00-1P 263855-01-2P 263855-02-3P 263855-03-4P 263855-04-5P 263855-09-0P 263855-10-3P 263855-11-4P 263855-12-5P 263855-13-6P 263855-14-7P 263855-15-8P 263855-20-5P 263855-21-6P 263855-22-7P 263855-23-8P 263855-24-9P 263855-25-0P 263855-33-0P 263855-34-1P 263855-36-3P 263855-37-4P 263855-40-9P 263855-41-0P 263855-42-1P 263855-43-2P 263855-44-3P 263855-45-4P 263855-46-5P 263855-47-6P 263855-50-1P 263855-51-2P 263855-52-3P 263855-54-5P 263855-55-6P 263855-56-7P 263855-57-8P 263855-58-9P 263855-59-0P

```
263855-60-3P 263855-61-4P 263855-63-6P
     263855-64-7P 263855-65-8P 263855-66-9P
     263855-67-0P 263855-68-1P 263855-69-2P
     263855-71-6P 263855-72-7P 263855-73-8P
     263855-74-9P 263855-77-2P 263855-80-7P
     263855-81-8P 263855-82-9P 263855-83-0P
     263855-84-1P 263855-85-2P 263855-86-3P
     263855-88-5P 263855-96-5P 263855-97-6P
     263855-99-8P 263856-00-4P 263856-01-5P
     263856-03-7P 263856-04-8P 263856-05-9P
     263856-06-0P 263856-07-1P 263856-08-2P
     263856-09-3P 263856-16-2P 263856-17-3P
     263856-21-9P 263856-22-0P 263856-23-1P
     263856-24-2P 263856-25-3P 263856-27-5P
     263856-29-7P 263856-31-1P 263856-32-2P
     263856-33-3P 263856-34-4P 263856-35-5P
     263856-36-6P 263856-38-8P 263856-39-9P
     263856-40-2P 263856-41-3P 263856-42-4P
     263856-43-5P 263856-44-6P 263856-45-7P
     263856-46-8P 263856-47-9P 263856-48-0P
     263856-49-1P 263856-50-4P 263856-51-5P
     263856-52-6P 263856-53-7P 263856-54-8P
     263856-55-9P 263856-56-0P 263856-57-1P
     RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (target compd.; prepn. of non-peptide GnRH agents for regulating
        gonadotropin secretion)
RN
     263852-86-4 CAPLUS
CN
     2-Furancarboxamide, N-[(1R,2S)-1-(hydroxymethyl)-2-methylbutyl]-5-
     [(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
     (CA INDEX NAME)
```

Absolute stereochemistry.

RN 263852-87-5 CAPLUS CN .beta.-Alanine, N-[[5-[(5,6,7,8-

.beta.-Alanine, N-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263852-88-6 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxy-1-methylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-90-0 CAPLUS

CN 2-Furancarboxamide,

N-propyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-91-1 CAPLUS

CN 2-Furancarboxamide, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $CH_2$ 

O  $CH_2$ 

Me Me Me Me

RN 263852-92-2 CAPLUS

CN 2-Furancarboxamide, N-(2,2-diethoxyethyl)-N-(2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 O  $CH_2$   $-CH_2$   $-Ph$   $||$   $||$   $|$   $CH_2$   $-CH_2$   $-CH$ 

RN 263852-93-3 CAPLUS

CN 2-Furancarboxamide,

N-[(2,3-dimethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263852-94-4 CAPLUS

CN 2-Furancarboxamide, N-(3-cyclohexen-1-ylmethyl)-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-95-5 CAPLUS

CN 2-Furancarboxamide, N-[3-(dibutylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263852-98-8 CAPLUS

CN 2-Furancarboxamide, N-butyl-N-(1-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263852-99-9 CAPLUS

CN 2-Furancarboxamide,

N-[(3,4-dichlorophenyl)methyl]-N-(3-pyridinylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263853-00-5 CAPLUS

CN 2-Furancarboxamide, N-propyl-N-[2-(2-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-02-7 CAPLUS

CN 2-Furancarboxamide, N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-03-8 CAPLUS

CN 2-Furancarboxamide, N,N-bis[3-(dimethylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $C$ 

RN 263853-06-1 CAPLUS

CN 2-Furancarboxamide, N-[(2-fluorophenyl)methyl]-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-08-3 CAPLUS

CN 2-Furancarboxamide, N-(2-cyanoethyl)-N-(2-furanylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2-CH_2-CN$$
 $CH_2$ 
 $CH_2$ 

RN 263853-09-4 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)-3-methylbutyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-10-7 CAPLUS

CN 2-Furancarboxamide, N-[3-(diethylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O

C-NH-( $CH_2$ ) 3-NEt2

Me Me

RN 263853-11-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-(phenylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263853-13-0 CAPLUS

CN 2-Furancarboxamide,

N-(cyclopropylmethyl)-N-propyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-14-1 CAPLUS

CN 2-Furancarboxamide,

N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)

RN 263853-16-3 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263853-17-4 CAPLUS

CN Ethanaminium, N,N,N-trimethyl-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263853-18-5 CAPLUS

CN 2-Furancarboxamide, N-[3-(dimethylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $C-NH-(CH_2)_3-NMe_2$ 
Me Me Me

RN 263853-19-6 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-N-2-propenyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-20-9 CAPLUS

CN 2-Furancarboxamide, N-(trans-4-hydroxycyclohexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263853-22-1 CAPLUS

CN 2-Furancarboxamide, N-cyclopentyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-23-2 CAPLUS

CN 2-Furancarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $C$ 

RN 263853-24-3 CAPLUS

CN Butanoic acid, 3-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263853-26-5 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-(1-methyl-3-pyrrolidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

263853-27-6 CAPLUS RN CN 2-Furancarboxamide, N-cyclohexyl-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-28-7 CAPLUS

2-Furancarboxamide, N-[1-(hydroxymethyl)pentyl]-5-[(5,6,7,8-tetrahydro-CN 3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-29-8 CAPLUS

CN 2-Furancarboxamide, N-[2-(diethylamino)ethyl]-N-ethyl-5-[(5,6,7,8tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O Et

|| |

C-N-CH\_2-CH\_2-NEt\_2

Me Me Me

RN 263853-33-4 CAPLUS

CN 2-Furancarboxamide,

N-[3-[(2-ethylhexyl)oxy]propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $O$   $C-NH-(CH_2)_3-O-CH_2-CH-Bu-n$  Me Me Me

RN 263853-34-5 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 263853-35-6 CAPLUS

CN 2-Furancarboxamide, N-(4-methylcyclohexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-38-9 CAPLUS

CN 2-Furancarboxamide, N-(1-ethynylcyclohexyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C-NH$   $C=C$ 

RN 263853-39-0 CAPLUS CN 2-Furancarboxamide,

N-[2-(3,4-dimethoxyphenyl)ethyl]-N-(2-methylpropyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263853-40-3 CAPLUS

CN 2-Furancarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-43-6 CAPLUS

CN 2-Furancarboxamide, N-[(2-chlorophenyl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-45-8 CAPLUS CN 2-Furancarboxamide,

N-(1,3-benzodioxol-5-ylmethyl)-N-(4-pyridinylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me Me O 
$$CH_2$$
 O  $CH_2$  O

RN 263853-46-9 CAPLUS

CN 2-Furancarboxamide,

N-(2-cyanoethyl)-N-cyclopentyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-51-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263853-52-7 CAPLUS

CN 2-Furancarboxamide, N-[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me O 
$$CH_2$$
 O  $CH_2$  O  $CH_2$  Ph Me Me Me

RN 263853-55-0 CAPLUS

CN 2-Furancarboxamide, N-(4-hydroxybutyl)-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-56-1 CAPLUS

CN 2-Furancarboxamide,

N-(1,2-diethyl-4-pyrazolidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-57-2 CAPLUS

CN 2-Furancarboxamide, N-(1-naphthalenylmethyl)-N-(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-58-3 CAPLUS CN 2-Furancarboxamide,

N-pentyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $C-NH-(CH_2)_4-Me$ 

Me Me Me

RN 263853-59-4 CAPLUS

CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263853-60-7 CAPLUS

CN 2-Furancarboxamide, N-(2-phenylpropyl)-N-(3-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-62-9 CAPLUS

CN 2-Furancarboxamide, N-[(4-hydroxyphenyl)methyl]-N-[1-(phenylmethyl)-3-pyrrolidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-63-0 CAPLUS

CN 2-Furancarboxamide,

pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263853-64-1 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-(4-hydroxybutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-65-2 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-(1-methyl-2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-67-4 CAPLUS

CN 2-Furancarboxamide, N-[4-(diethylamino)-1-methylbutyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263853-68-5 CAPLUS

CN 2-Furancarboxamide, N,N-bis(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $CH_2$ 

O  $CH_2$ 

Me Me Me

RN 263853-70-9 CAPLUS

CN 2-Furancarboxamide, N-[(3,4-dichlorophenyl)methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-71-0 CAPLUS

CN 2-Furancarboxamide, N-[1-(4-methylphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-73-2 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-78-7 CAPLUS

CN 2-Furancarboxamide,

N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(4-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(dimethylamino)propoxy]phenyl]methyl]-N-[3-(dimethylamino)propoxy]phenyl]methylaminopropoxy]phenylamin

methyl-1-piperazinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-79-8 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-1H-inden-1-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-80-1 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$Me$$
 O  $CH_2-Ph$ 

$$CH_2 \longrightarrow CH_2-Ph$$
Me Me Me Me

RN 263853-81-2 CAPLUS

CN Alanine, 2-methyl-N-[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 263853-82-3 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydroxypropyl)-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-86-7 CAPLUS

CN 2-Furancarboxamide, N-[(2,4-dichlorophenyl)methyl]-N-(3-hydroxypropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-87-8 CAPLUS

CN 2-Furancarboxamide, N-butyl-N-(2-cyanoethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-88-9 CAPLUS

CN 2-Furancarboxamide,

N-(2,2-diethoxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-91-4 CAPLUS

CN 2-Furancarboxamide, N-[(4-ethylphenyl)methyl]-N-(3-hydroxypropyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263853-92-5 CAPLUS

CN 2-Furancarboxamide, N-cyclopentyl-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263853-93-6 CAPLUS

CN 2-Furancarboxamide, N-[4-(diethylamino)butyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $C-NH-(CH_2)_4-NEt_2$ 
Me Me Me

RN 263853-95-8 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxyethyl)-N-(2-methylbutyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2-CH_2-OH$$

$$CH_2 - CH_2-CH-Et$$
Me Me Me

RN 263853-97-0 CAPLUS

CN 2-Furancarboxamide, N-[2-methyl-1-(1-methylethyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-NH-CH(Pr-i)_2$  Me Me Me

RN 263853-98-1 CAPLUS

CN 2-Furancarboxamide,

N, N-bis[3-(diethylamino)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-00-8 CAPLUS

CN 2-Furancarboxamide, N-cyclopentyl-N-2-propenyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263854-01-9 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-(3-phenylbicyclo[2.2.1]hept-2-yl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263854-02-0 CAPLUS

CN 2-Furancarboxamide, N-butyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-04-2 CAPLUS

CN 2-Furancarboxamide, N-[3-(diethylamino)propyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-06-4 CAPLUS

CN 2-Furancarboxamide, N-[2-(butylethylamino)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me CH<sub>2</sub> 
$$CH_2$$
  $CH_2$   $CH$ 

RN 263854-09-7 CAPLUS

CN 2-Furancarboxamide, N-[4-(diethylamino)-1-methylbutyl]-N-[(4-fluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me 
$$CH-(CH_2)_3-NEt_2$$
Me Me  $CH_2$ 
 $CH_2$ 

RN 263854-11-1 CAPLUS

CN 2-Furancarboxamide,

N-[2-(3,4-dimethoxyphenyl)ethyl]-N-(2-phenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-12-2 CAPLUS

CN 2-Furancarboxamide, N-(1-methylpropyl)-N-propyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-13-3 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-(1-naphthalenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-15-5 CAPLUS
CN 2-Furancarboxamide,
N-[(4-methylphenyl)methyl]-N-[3-(4-morpholinyl)propyl]5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)
(CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263854-16-6 CAPLUS
CN 2-Furancarboxamide, N-(2-cyanoethyl)-N-propyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O  $Pr-n$ 
 $C-N-CH_2-CH_2-CN$ 

Me Me Me

RN 263854-20-2 CAPLUS
CN 2-Furancarboxamide, N-[2-(4-bromophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-21-3 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxy-3-phenylpropyl)-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-25-7 CAPLUS

CN 2-Furancarboxamide, N-[1-(methoxymethyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 O  $CH_2$ —OMe  $CH_2$ 

RN 263854-60-0 CAPLUS

CN 2-Furancarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-61-1 CAPLUS

CN 2-Furancarboxamide,

N-(2,2-diphenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263854-62-2 CAPLUS

CN 2-Furancarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-63-3 CAPLUS

CN 2-Furancarboxamide, N-[4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-64-4 CAPLUS

CN 2-Furancarboxamide, N-[2-[(pyrazinylamino)carbonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-65-5 CAPLUS

CN 2-Furancarboxamide, N-[5-[(4-nitrophenyl)sulfonyl]-2-thiazolyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263854-66-6 CAPLUS

CN 2-Furancarboxamide, N-[[(1R, 4aS, 10aR)-1, 2, 3, 4, 4a, 9, 10, 10a-octahydro-1, 4a-

dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263854-67-7 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-aminophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263854-68-8 CAPLUS

CN Hexanoic acid, 6-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $C$ 

RN 263854-69-9 CAPLUS

CN 2-Furancarboxamide, N-[[9-[(2,5-dichlorophenyl)methyl]-9H-pyrido[3,4-b]indol-3-yl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-70-2 CAPLUS CN 2-Furancarboxamide,

N-[[3-[[[phenyl(phenylmethyl)amino]carbonyl]amino]phen

yl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-71-3 CAPLUS

CN 2-Furancarboxamide,

N-(2-[1,1'-biphenyl]-4-ylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-72-4 CAPLUS

CN 2-Furancarboxamide, N-[2-[[2-[[(tetrahydro-2-furanyl)methyl]amino]-4-

pyrimidinyl]amino]cyclohexyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-73-5 CAPLUS

CN 2-Furancarboxamide, N-[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263854-74-6 CAPLUS

CN 2-Furancarboxamide, N-[1-(phenylmethyl)-4-piperidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-75-7 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263854-76-8 CAPLUS

CN 2-Furancarboxamide,

N, N-bis (phenylmethyl) -5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl] - (9CI) (CA INDEX NAME)

RN 263854-77-9 CAPLUS

CN 2-Furancarboxamide, N-(diphenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-78-0 CAPLUS

CN 2-Furancarboxamide, N-[(1R,2R)-2-hydroxy-1,2-diphenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263854-79-1 CAPLUS

CN 2-Furancarboxamide, N-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263854-80-4 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$

O Me  $CH_2$ 

O  $CH_2$ 

Me Me Me

RN 263854-81-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263854-82-6 CAPLUS

CN 2-Furancarboxamide,

 $\begin{tabular}{ll} N-(1,2-diphenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME) \\ \end{tabular}$ 

RN 263854-83-7 CAPLUS

CN 2-Furancarboxamide, N-(3,3-diphenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-84-8 CAPLUS

CN 2-Furancarboxamide, N-[(1R)-2-hydroxy-1-phenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263854-85-9 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

RN 263854-87-1 CAPLUS
CN 2-Furancarboxamide,
N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)

(CA INDEX NAME)

Absolute stereochemistry.

RN 263854-88-2 CAPLUS
CN 2-Furancarboxamide,
N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 263854-89-3 CAPLUS
CN 2-Furancarboxamide,
N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 263854-91-7 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[2-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263854-92-8 CAPLUS

CN 2-Furancarboxamide,

N-[(2,6-dimethoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-93-9 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-[2-(2-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 O Me  $CH_2$   $CH_$ 

RN 263854-94-0 CAPLUS

CN 2-Furancarboxamide, N-[(2-hydroxyphenyl)methyl]-N-(2-phenylethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263854-95-1 CAPLUS

CN 2-Furancarboxamide,

N-(3-hydroxypropyl)-N-(2-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263854-96-2 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-(4-pyridinylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-97-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-methoxyphenyl)-1-methylethyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263854-98-4 CAPLUS

CN 2-Furancarboxamide, N-butyl-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O CH2-Ph 
$$\parallel \parallel \parallel$$
 CH2-N-Bu-n Me Me Me

RN 263854-99-5 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxyethyl)-N-(phenylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-00-1 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-N-(2-hydroxy-2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-01-2 CAPLUS
CN 2-Furancarboxamide,
N-[bis(4-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-02-3 CAPLUS CN 2-Furancarboxamide,

N-[3-[(diphenylmethyl)amino]-3-oxopropyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-03-4 CAPLUS

CN 2-Furancarboxamide, N-[4-[(diphenylmethyl)amino]-4-oxobutyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_$ 

RN 263855-04-5 CAPLUS

CN 2-Furancarboxamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263855-09-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester

(9CI) (CA INDEX NAME)

RN 263855-10-3 CAPLUS

CN 2-Furancarboxamide, N-(1,2,3,4-tetrahydro-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-11-4 CAPLUS

CN 2-Furancarboxamide, N-[[(1R,2S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 263855-12-5 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-hydroxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263855-13-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(3-chlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-14-7 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-15-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263855-20-5 CAPLUS

CN 2-Furancarboxamide,

N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-21-6 CAPLUS
CN 2-Furancarboxamide,
N-[(2,5-dichlorophenyl)methyl]-5-[(5,6,7,8-tetrahydro3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-22-7 CAPLUS
CN 2-Furancarboxamide,
N-[2-(2,6-dichlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-23-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 263855-24-9 CAPLUS

CN 2-Furancarboxamide, N-[(2-chloro-6-phenoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-25-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-33-0 CAPLUS

CN 2-Furancarboxamide, N-[1-(4-chlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-34-1 CAPLUS

CN 2-Furancarboxamide, N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263855-36-3 CAPLUS

CN 2-Furancarboxamide, N-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me CH2 
$$CH_2$$
  $CH_2$   $CH_2$ 

RN 263855-37-4 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-[(2-hydroxy-5-nitrophenyl)methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263855-40-9 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263855-41-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[ethyl(3-methylphenyl)amino]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-42-1 CAPLUS

CN 2-Furancarboxamide, N-methyl-N-(2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-43-2 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-1H-inden-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-44-3 CAPLUS

CN 2-Furancarboxamide, N-[(4-chlorophenyl)methyl]-N-[2-(1-methyl-2-

pyrrolidinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-45-4 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxypropyl)-N-[(2-nitrophenyl)methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me HO- (CH<sub>2</sub>) 3 
$$O_2N$$

CH<sub>2</sub>

O

CH<sub>2</sub>

O

CH<sub>2</sub>

Me

Me Me

RN 263855-46-5 CAPLUS

CN 2-Furancarboxamide,

N-[2-(3,4-dichlorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-47-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-ethylphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-50-1 CAPLUS

CN 2-Furancarboxamide, N-[1-(4-fluorophenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-51-2 CAPLUS

CN 2-Furancarboxamide,

N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me OMe OMe OMe 
$$CH_2$$
  $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$   $CH_2$ 

RN 263855-52-3 CAPLUS

CN 2-Furancarboxamide, N-[(2-chlorophenyl)methyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-54-5 CAPLUS

CN 2-Furancarboxamide,

N-(1,1-dimethyl-2-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263855-55-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-fluorophenyl)-1,1-dimethylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-56-7 CAPLUS

CN 2-Furancarboxamide, N-(1-methyl-1-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-57-8 CAPLUS

CN 2-Furancarboxamide, N-(2-hydroxy-2-phenylethyl)-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-58-9 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-59-0 CAPLUS

CN 2-Furancarboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-60-3 CAPLUS

CN 2-Furancarboxamide,

N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-61-4 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxy-1-phenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-63-6 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-[2-(2-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-64-7 CAPLUS

CN 2-Furancarboxamide, N-[(4-chlorophenyl)phenylmethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-65-8 CAPLUS

CN 2-Furancarboxamide, N-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-66-9 CAPLUS

CN 2-Furancarboxamide, N-(2,2-diphenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-67-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-68-1 CAPLUS

CN 2-Furancarboxamide,

N-[2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-69-2 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-1-(1H-imidazol-4-ylmethyl)ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263855-71-6 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-N-

RN 263855-72-7 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263855-73-8 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-74-9 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-1-[(4-hydroxyphenyl)methyl]ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263855-77-2 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydroxypropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-80-7 CAPLUS

CN 2-Furancarboxamide, N-(1-naphthalenylmethyl)-N-(3-pyridinylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263855-81-8 CAPLUS

CN 2-Furancarboxamide, N, N-bis(2-hydroxyethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me O 
$$CH_2-CH_2-OH$$

$$CH_2-CH_2-OH$$

$$CH_2-CH_2-OH$$

$$Me$$
Me Me Me

RN 263855-82-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-N-[(4-methylphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-83-0 CAPLUS

CN 2-Furancarboxamide, N-ethyl-N-[(2-fluorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-84-1 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)-2,2-dimethylpropyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-85-2 CAPLUS

CN 2-Furancarboxamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-86-3 CAPLUS

CN Butanoic acid, 3-[(aminocarbonyl)amino]-3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263855-88-5 CAPLUS

CN 2-Furancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-96-5 CAPLUS

CN 2-Furancarboxamide, N-[(2-chlorophenyl)methyl]-N-(2,2-diphenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-97-6 CAPLUS

CN 2-Furancarboxamide,

N-[(4-methoxyphenyl)methyl]-N-[2-(2-pyridinyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263855-99-8 CAPLUS

CN 2-Furancarboxamide,

N-(7-hydroxy-3,7-dimethyloctyl)-N-(3-hydroxypropyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263856-00-4 CAPLUS

CN 2-Furancarboxamide, N-[(4-phenoxyphenyl)methyl]-N-(3-phenylpropyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263856-01-5 CAPLUS

CN 2-Furancarboxamide, N-[(1R)-2,3-dihydro-1H-inden-1-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263856-03-7 CAPLUS

CN 2-Furancarboxamide, N-(2-cyanoethyl)-N-[(tetrahydro-2-furanyl)methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263856-04-8 CAPLUS

CN 2-Furancarboxamide,

N, N-bis[(3-chlorophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$C1$$

O  $CH_2$ 

O  $CH_2$ 

O  $CH_2$ 

Me Me Me

RN 263856-05-9 CAPLUS

CN 2-Furancarboxamide,

N, N-bis(cyanomethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-06-0 CAPLUS

CN 2-Furancarboxamide, N-[1,1'-bicyclohexyl]-2-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-07-1 CAPLUS

CN 2-Furancarboxamide, N-(2,2-diethoxyethyl)-N-(4-pyridinylmethyl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263856-08-2 CAPLUS

CN 2-Furancarboxamide,

N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 O  $CH_2$  OH  $CH_2$  OH  $CH_2$  OH  $CH_2$  OH  $CH_2$  OH  $CH_2$  OH

RN 263856-09-3 CAPLUS

CN 2-Furancarboxamide, N-[2,5-dioxo-1-(phenylmethyl)-3-pyrrolidinyl]-N-(2-furanylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-16-2 CAPLUS

CN 2-Furancarboxamide, N-[1-(1-naphthalenyl)ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-17-3 CAPLUS

CN 2-Furancarboxamide,

N-[(2-hydroxycyclohexyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-21-9 CAPLUS

CN 2-Furancarboxamide, N-(3,3-diphenylpropyl)-N-(1-phenylethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-22-0 CAPLUS

CN 2-Furancarboxamide,

N-[3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)propyl]-N-

RN 263856-23-1 CAPLUS

CN 2-Furancarboxamide, N-cyclohexyl-N-(1H-indol-3-ylmethyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-24-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263856-25-3 CAPLUS

CN 2-Furancarboxamide,

N-[2-(dimethylamino)ethyl]-N-[(3-nitrophenyl)methyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263856-27-5 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)

RN 263856-29-7 CAPLUS

CN 2-Furancarboxamide, N-[(1R)-1-phenylethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 263856-31-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-cyanophenyl)-2-hydroxyethyl]-N-methyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-32-2 CAPLUS

CN 2-Furancarboxamide, N-(3,3-diphenylpropyl)-N-[(2-methoxyphenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-33-3 CAPLUS
CN 2-Furancarboxamide,
N-(1,3-benzodioxol-5-ylmethyl)-N-(3,3-diphenylpropyl)5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)
(CA INDEX NAME)

RN 263856-34-4 CAPLUS

CN 2-Furancarboxamide, N-(3,3-diphenylpropyl)-N-[(1-methyl-1H-pyrrol-2-yl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-35-5 CAPLUS

CN 2-Furancarboxamide, N-(cyclohexylmethyl)-N-(3,3-diphenylpropyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)

## (CA INDEX NAME)

Me Me Me 
$$CH_2-CH_2-CHPh_2$$
 $CH_2-CH_2-CHPh_2$ 
 $CH_2-CH_2-CHPh_2$ 
 $CH_2-CH_2-CHPh_2$ 
 $CH_2-CH_2-CHPh_2$ 
 $CH_2-CH_2-CHPh_2$ 

RN 263856-36-6 CAPLUS

CN 2-Furancarboxamide, N-[(4-hydroxyphenyl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-38-8 CAPLUS

CN 2-Furancarboxamide, N-[1,1-dimethyl-2-[(trifluoroacetyl)amino]ethyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-39-9 CAPLUS

CN 2-Furancarboxamide, N-[1-(hydroxymethyl)-2-methylbutyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-40-2 CAPLUS

CN 2-Furancarboxamide, N-(1,5-dihydro-3-phenyl-5-thioxo-4H-1,2,4-triazol-4-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263856-41-3 CAPLUS

CN 2-Furancarboxamide,

N-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-42-4 CAPLUS

CN 2-Furancarboxamide, N-[1,5-dihydro-3-(4-pyridinyl)-5-thioxo-4H-1,2,4-triazol-4-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-43-5 CAPLUS

CN 2-Furancarboxamide,

N-(2,6-dimethyl-4-oxo-3(4H)-quinazolinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-44-6 CAPLUS

CN 2-Furancarboxamide, N-[2-amino-6-oxo-4-(trifluoromethyl)-1(6H)-pyrimidinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 
 $CH_2$ 
 $CH_2$ 
 $CH_3$ 
 $CF_3$ 

RN 263856-45-7 CAPLUS

CN 2-Furancarboxamide, N-2-pyridinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-46-8 CAPLUS

CN 2-Furancarboxamide, N-(4,5-dimethyl-2-thiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-47-9 CAPLUS

CN 2-Furancarboxamide, N-(5-chloro-2-cyanophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-48-0 CAPLUS

CN 2-Furancarboxamide, N-(4,6-dimethyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-49-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(1H-indol-2-yl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-50-4 CAPLUS

CN 2-Furancarboxamide, N-2-pyrimidinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-51-5 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)

RN 263856-52-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263856-53-7 CAPLUS

CN 2-Furancarboxamide, N-[2-(aminocarbonyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$H_2N-C$$
 $CH_2$ 
 $CH_2$ 

RN 263856-54-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-1,2,4-triazin-3-yl- (9CI) (CA INDEX NAME)

RN 263856-55-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(2-hydroxyethyl)-6-methylphenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me HO-CH<sub>2</sub>-CH<sub>2</sub>

$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263856-56-0 CAPLUS CN 4-Thiazoleacetic acid,

2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263856-57-1 CAPLUS

CN 2-Furancarboxamide, N-(4-methyl-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

IT 263856-58-2P 263856-59-3P 263856-60-6P 263856-61-7P 263856-62-8P 263856-63-9P 263856-64-0P 263856-65-1P 263856-66-2P 263856-67-3P 263856-68-4P 263856-69-5P 263856-70-8P 263856-71-9P 263856-72-0P 263856-73-1P 263856-74-2P 263856-75-3P 263856-76-4P 263856-77-5P 263856-78-6P 263856-79-7P 263856-80-0P 263856-81-1P 263856-82-2P 263856-83-3P 263856-85-5P 263856-86-6P 263856-87-7P 263856-88-8P 263856-89-9P 263856-90-2P 263856-91-3P 263856-92-4P 263856-93-5P 263856-94-6P

```
263856-95-7P 263856-96-8P 263856-97-9P
    263856-98-0P 263856-99-1P 263857-00-7P
    263857-01-8P 263857-02-9P 263857-03-0P
    263857-04-1P 263857-05-2P 263857-06-3P
    263857-07-4P 263857-08-5P 263857-09-6P
    263857-10-9P 263857-11-0P 263857-12-1P
    263857-13-2P 263857-14-3P 263857-15-4P
    263857-16-5P 263857-17-6P 263857-18-7P
    263857-19-8P 263857-20-1P 263857-21-2P
    263857-22-3P 263857-23-4P 263857-24-5P
    263857-25-6P 263857-26-7P 263857-27-8P
    263857-28-9P 263857-29-0P 263857-30-3P
    263857-31-4P 263857-32-5P 263857-33-6P
    263857-34-7P 263857-35-8P 263857-36-9P
    263857-37-0P 263857-38-1P 263857-39-2P
    263857-40-5P 263857-41-6P 263857-42-7P
    263857-43-8P 263857-44-9P 263857-45-0P
    263857-46-1P 263857-47-2P 263857-48-3P
    263857-49-4P 263857-50-7P 263857-51-8P
    263857-52-9P 263857-53-0P 263857-54-1P
    263857-55-2P 263857-56-3P 263857-57-4P
    263857-58-5P 263857-59-6P 263857-60-9P
    263857-61-0P 263857-62-1P 263857-63-2P
    263857-64-3P 263857-65-4P 263857-66-5P
    263857-67-6P 263857-68-7P 263857-69-8P
    263857-70-1P 263857-71-2P 263857-72-3P
    263857-73-4P 263857-74-5P 263857-75-6P
    263857-76-7P 263857-77-8P 263857-78-9P
    263857-79-0P 263857-80-3P 263857-81-4P
    263857-82-5P 263857-83-6P 263857-84-7P
    263857-85-8P 263857-86-9P 263857-87-0P
    263857-88-1P 263857-89-2P 263857-90-5P
    263857-91-6P 263857-92-7P 263857-93-8P
    263857-94-9P 263857-95-0P 263857-96-1P
    263857-97-2P 263857-98-3P 263857-99-4P
    263858-00-0P 263858-01-1P 263858-02-2P
    263858-03-3P 263858-04-4P 263858-05-5P
    263858-06-6P 263858-07-7P 263858-08-8P
    263858-09-9P 263858-10-2P 263858-11-3P
    263858-12-4P 263858-13-5P 263858-14-6P
    263858-15-7P 263858-16-8P 263858-17-9P
    263858-18-0P 263858-19-1P 263858-20-4P
    263858-21-5P 263858-22-6P 263858-23-7P
    263858-24-8P
    RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
    study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
    BIOL (Biological study); PREP (Preparation); USES (Uses)
        (target compd.; prepn. of non-peptide GnRH agents for regulating
       gonadotropin secretion)
    263856-58-2 CAPLUS
    2-Furancarboxamide, N-(4-chloro-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-
    3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)
```

RN

CN

RN 263856-59-3 CAPLUS

CN 2-Furancarboxamide, N-(6-methyl-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-60-6 CAPLUS

CN 2-Furancarboxamide, N-(6-ethoxy-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-61-7 CAPLUS

CN 2-Furancarboxamide, N-[4-(4-chloro-3-methylphenyl)-2-thiazolyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

- RN 263856-62-8 CAPLUS
- CN 2-Furancarboxamide, N-[4-(1,1-dimethylethyl)-2-thiazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

- RN 263856-63-9 CAPLUS
- CN 2-Furancarboxamide, N-[4-(4-bromophenyl)-2-thiazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

- RN 263856-64-0 CAPLUS
- CN 2-Furancarboxamide, N-[4-(4-chlorophenyl)-2-thiazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

- RN 263856-65-1 CAPLUS
- CN 2-Furancarboxamide, N-(6-fluoro-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-66-2 CAPLUS

CN 2-Furancarboxamide,

N-(4-methoxy-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-67-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

RN 263856-68-4 CAPLUS

CN 2-Furancarboxamide, N-(3-methyl-5-isothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-69-5 CAPLUS

CN 2-Furancarboxamide, N-(4-methyl-2-thiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-70-8 CAPLUS

CN 2-Furancarboxamide, N-(5-chloro-2-benzoxazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-71-9 CAPLUS

CN 2-Furancarboxamide, N-(5-methyl-3-isoxazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-72-0 CAPLUS

CN 2-Furancarboxamide, N-(5-phenyl-1H-pyrazol-3-yl)-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-73-1 CAPLUS

CN 2-Furancarboxamide, N-(5-methyl-1H-pyrazol-3-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-74-2 CAPLUS

CN 2-Furancarboxamide, N-(4-methyl-2-oxazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-75-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CAINDEX NAME)

RN 263856-76-4 CAPLUS

CN 2-Furancarboxamide, N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-77-5 CAPLUS

CN 2-Furancarboxamide,

N-(6-methoxy-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-78-6 CAPLUS

CN 4-Thiazoleacetic acid, .alpha.-oxo-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester

(9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $C-C-OEt$   $C-MH$   $C-C-OEt$   $C-MH$   $C-C-OEt$ 

RN 263856-80-0 CAPLUS

CN 2-Furancarboxamide, N-(2,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263856-81-1 CAPLUS

CN 2-Furancarboxamide, N-2-benzothiazolyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-82-2 CAPLUS

CN 2-Furancarboxamide, N-[1-(3-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-83-3 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[5-(2-thienyl)-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)

RN 263856-85-5 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(4-fluorophenyl)-5-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263856-86-6 CAPLUS

CN 2-Furancarboxamide, N-(3-phenyl-1,2,4-thiadiazol-5-yl)-5-[(5,6,7,8-

tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-87-7 CAPLUS

CN 2-Furancarboxamide, N-(5,6-dimethyl-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263856-88-8 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

RN 263856-89-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263856-95-7 CAPLUS
CN 2-Thiophenecarboxylic acid,
5-(4-fluorophenyl)-3-[[[5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263856-96-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1,1-dimethylethyl)-3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263856-97-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 4-cyano-5-(dimethylamino)-3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263856-98-0 CAPLUS

CN [2,3'-Bithiophene]-5-carboxylic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263856-99-1 CAPLUS

CN 2-Thiophenecarboxylic acid,

5-[4-(2-methylpropyl)phenyl]-3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263857-00-7 CAPLUS

CN 2-Furancarboxamide, N-3-isoxazolyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-01-8 CAPLUS

CN 2-Furancarboxamide, N-(1-methyl-1H-benzimidazol-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-02-9 CAPLUS

CN 2-Furancarboxamide, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263857-03-0 CAPLUS

CN 2-Furancarboxamide,

N-[1-(phenylmethyl)-1H-benzimidazol-2-yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-04-1 CAPLUS

CN 2-Furancarboxamide, N-[4-(2-naphthalenyl)-2-thiazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-05-2 CAPLUS

CN 2-Furancarboxamide, N-[1-methyl-5-(methylthio)-1H-1,2,4-triazol-3-yl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263857-06-3 CAPLUS

CN 2-Furancarboxamide, N-[4-(4-methylphenyl)-2-thiazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-07-4 CAPLUS

CN 2-Furancarboxamide, N-[4-(1-naphthalenyl)-2-thiazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-08-5 CAPLUS

CN 2-Furancarboxamide, N-(4-bromo-5-methyl-3-isoxazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-09-6 CAPLUS

CN 2-Furancarboxamide, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-10-9 CAPLUS

CN 2-Furancarboxamide,

 $\begin{tabular}{ll} N-[4-(3-chloro-4-methylphenyl)-5-methyl-2-thiazolyl]-5- & [(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) & (CA INDEX NAME) &$ 

Me Me Me 
$$CH_2$$
 O  $C-NH$  Me Me Me Me

RN 263857-11-0 CAPLUS

CN Benzoic acid,

3-methyl-4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263857-12-1 CAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263857-13-2 CAPLUS

CN 2-Furancarboxamide,

N-(4,6-dimethyl-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263857-14-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(4-morpholinyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-15-4 CAPLUS

CN 2-Furancarboxamide, N-[(2-aminophenyl)methyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263857-16-5 CAPLUS

CN 2-Furancarboxamide, N-[2-[[[1-(phenylmethyl)-3-pyrrolidinyl]amino]carbonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-17-6 CAPLUS

CN 2-Furancarboxamide, N-[2-[[(4-pyridinylmethyl)amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263857-18-7 CAPLUS

CN Glycine, N-[2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 263857-19-8 CAPLUS
CN 2-Furancarboxamide,
N-[2-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me Et<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-NH-C

$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 263857-20-1 CAPLUS

CN 2-Furancarboxamide, N-[2-[(phenylamino)carbonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-21-2 CAPLUS

CN 2-Furancarboxamide, N-[2-[(1H-benzimidazol-2-ylamino)carbonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-22-3 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[(2-methyl-4-quinolinyl)amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263857-23-4 CAPLUS

CN 2-Furancarboxamide, N-(6,7-dihydro-6-oxo-1H-purin-2-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $CH_2$   $NH$   $NH$   $NH$ 

RN 263857-24-5 CAPLUS

CN 2-Furancarboxamide, N-(2-methyl-5-benzoxazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-25-6 CAPLUS

CN 2-Furancarboxamide, N-(5,6-dimethyl-1,2,4-triazin-3-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-26-7 CAPLUS

CN 2-Furancarboxamide, N-(2-phenoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-27-8 CAPLUS CN 2-Furancarboxamide,

N-(4,6-dimethoxy-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-28-9 CAPLUS

CN Pyrazinecarboxylic acid, 5,6-dichloro-3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263857-29-0 CAPLUS

CN 2-Furancarboxamide, N-(1,4-dihydro-2,4-dioxo-2H-3,1-benzoxazin-6-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C-NH$   $C-NH$   $CH_2$   $C-NH$   $C-NH$   $C-NH$   $C-NH$   $C-NH$   $C-NH$   $C-NH$ 

RN 263857-30-3 CAPLUS

CN 2-Furancarboxamide, N-(2-benzoyl-4-chlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-31-4 CAPLUS

CN 2-Furancarboxamide, N-[2-(1H-benzimidazol-2-yl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-32-5 CAPLUS

CN 2-Furancarboxamide, N-(4-methoxy-6-methyl-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-33-6 CAPLUS

CN 2-Furancarboxamide, N-(4-fluorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-34-7 CAPLUS

CN 2-Furancarboxamide, N-(2-methoxy-5-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-35-8 CAPLUS

CN 2-Furancarboxamide, N-(4-methoxy-2-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-36-9 CAPLUS

CN 2-Furancarboxamide, N-(3-chlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-37-0 CAPLUS

CN 2-Furancarboxamide, N-(2-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $O$   $C-NH$   $Me$  Me Me

RN 263857-38-1 CAPLUS

CN 2-Furancarboxamide, N-(4-chlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-39-2 CAPLUS

CN 2-Furancarboxamide,

N-(2,3-dihydro-2-thioxo-6-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-40-5 CAPLUS

CN 2-Furancarboxamide, N-[4-[(4-nitrophenyl)sulfonyl]phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-41-6 CAPLUS

CN 2-Furancarboxamide, N-[2-methoxy-4-(phenylamino)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-42-7 CAPLUS

CN 2-Furancarboxamide, N-(3-hydroxy-2-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $O$   $C-NH$ 

RN 263857-43-8 CAPLUS

CN 2-Furancarboxamide,

N-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-44-9 CAPLUS

CN 2-Furancarboxamide,

N-(4,6-dichloro-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-45-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(hydroxyphenylmethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-46-1 CAPLUS

CN 2-Furancarboxamide,

N-(4,5-difluoro-2-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-47-2 CAPLUS

CN 2-Furancarboxamide, N-(2,5-dicyano-3,4,6-trifluorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-48-3 CAPLUS

CN 2-Furancarboxamide, N-(4-cyclohexylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-49-4 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 263857-50-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-thioxo-1H-benzimidazol-5-yl)-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

Me Me Me 
$$CH_2$$
  $C-NH$   $NH$   $NH$ 

RN 263857-51-8 CAPLUS

CN 2-Furancarboxamide, N-[2-bromo-4-(1-methylethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-52-9 CAPLUS

CN 2-Furancarboxamide,

N-[4-(1,1-dimethylethyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-53-0 CAPLUS

CN 2-Furancarboxamide, N-(6-nitro-5-quinolinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$O_2N$$

NH

 $CH_2$ 
 $O$ 
 $C=0$ 

RN 263857-54-1 CAPLUS

CN 2-Furancarboxamide, N-[2-nitro-5-(propylthio)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-55-2 CAPLUS

CN 2-Furancarboxamide, N-[4-(1-piperidinyl)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-56-3 CAPLUS

CN 2-Furancarboxamide, N-(1,2-dihydro-2-thioxo-4-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl}- (9CI) (CA INDEX NAME)

RN 263857-57-4 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dibromo-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-58-5 CAPLUS

CN 2-Furancarboxamide, N-[3-(phenylmethoxy)-2-pyridinyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-59-6 CAPLUS

CN 2-Furancarboxamide, N-(5-nitro-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-60-9 CAPLUS

CN 2-Furancarboxamide, N-(4-methyl-3-nitro-2-pyridinyl)-5-[(5,6,7,8-

tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-61-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[(phenylmethyl)amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263857-62-1 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)

(CA INDEX NAME)

RN 263857-63-2 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]phenyl]-

5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI)
(CA INDEX NAME)

RN 263857-64-3 CAPLUS

CN 2-Furancarboxamide, N-[1,1'-biphenyl]-3-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-65-4 CAPLUS

CN 2-Furancarboxamide, N-(4-methyl-5-nitro-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-66-5 CAPLUS

CN 2-Furancarboxamide, N-(5-chloro-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-67-6 CAPLUS

CN 2-Furancarboxamide, N-(5-methyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-68-7 CAPLUS

CN 2-Furancarboxamide, N-(6-methyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-69-8 CAPLUS

CN 2-Furancarboxamide, N-(4-methyl-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-70-1 CAPLUS

CN 2-Furancarboxamide, N-(4-bromo-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-71-2 CAPLUS

CN 2-Furancarboxamide, N-(4-cyano-2-nitrophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-72-3 CAPLUS

CN 2-Furancarboxamide, N-(5-chloro-2-methoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-73-4 CAPLUS

CN 2-Furancarboxamide, N-pyrazinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $CH_2$   $NH$   $NH$   $NH$   $NH$   $NH$ 

RN 263857-74-5 CAPLUS

CN 2-Furancarboxamide, N-[4-(phenylmethoxy)phenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $O$   $C$   $NH$   $O$   $CH_2$   $Ph$   $Me$  Me Me

RN 263857-75-6 CAPLUS

CN 2-Furancarboxamide,

N-(9,10-dihydro-9,10-dioxo-2-anthracenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-76-7 CAPLUS

CN 2-Furancarboxamide, N-(5-bromo-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-77-8 CAPLUS

CN 2-Furancarboxamide, N-(4-butoxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-78-9 CAPLUS

CN 2-Furancarboxamide, N-(6-chloro-3-pyridazinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-79-0 CAPLUS

CN 2-Furancarboxamide, N-(4-chloro-6-methyl-2-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-80-3 CAPLUS

CN Benzoic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 263857-81-4 CAPLUS

CN 2-Furancarboxamide, N-(3-chloro-4-cyanophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-82-5 CAPLUS

CN 2-Furancarboxamide, N-(4-cyano-2,3,5,6-tetrafluorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-83-6 CAPLUS

CN 2-Furancarboxamide, N-[5-(ethylsulfonyl)-2-hydroxyphenyl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-84-7 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dichlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-85-8 CAPLUS

CN 2-Furancarboxamide, N-(3,5-dichloro-4-hydroxyphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-86-9 CAPLUS

CN 2-Furancarboxamide, N-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263857-87-0 CAPLUS

CN Benzoic acid, 4-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

RN 263857-88-1 CAPLUS

CN 2-Furancarboxamide, N-(6-acetyl-1,3-benzodioxol-5-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-89-2 CAPLUS

CN 2-Furancarboxamide, N-2-quinolinyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-90-5 CAPLUS

CN 2-Furancarboxamide, N-(4-ethyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-91-6 CAPLUS

CN 2-Furancarboxamide, N-(6-ethyl-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-92-7 CAPLUS

CN 2-Furancarboxamide, N-(2-bromo-4-chlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-93-8 CAPLUS

CN Pyrazinecarboxylic acid,

3-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI)

(CA

INDEX NAME)

RN 263857-94-9 CAPLUS

CN Benzoic acid, 3,5-dibromo-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263857-95-0 CAPLUS

CN Benzoic acid,

4-chloro-2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 263857-96-1 CAPLUS

CN Benzoic acid, 2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)

RN 263857-97-2 CAPLUS

CN 2-Furancarboxamide,

N-(4,6-dichloro-5-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Me Me 
$$CH_2$$
  $CH_2$   $C$ 

RN 263857-98-3 CAPLUS

CN 2-Furancarboxamide, N-1H-purin-6-yl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263857-99-4 CAPLUS

CN 2-Furancarboxamide, N-(2-chloro-5-fluoro-4-pyrimidinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-00-0 CAPLUS

CN 2-Furancarboxamide,

N-(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-01-1 CAPLUS

CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(2,3,5-trimethylphenyl)- (9CI) (CA INDEX NAME)

RN 263858-02-2 CAPLUS

CN 2-Furancarboxamide, N-(5-bromo-2-pyridinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-03-3 CAPLUS

CN 2-Furancarboxamide,

N-(2,3-dihydro-2-methyl-1,3-dioxo-1H-isoindol-5-yl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-04-4 CAPLUS

CN 2-Furancarboxamide, N-(1,2,3,4-tetrahydro-1,4-dioxo-6-phthalazinyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-05-5 CAPLUS

CN 2-Furancarboxamide, N-(4-hydroxy-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-06-6 CAPLUS

CN 2-Furancarboxamide, N-(2,5-dichlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-07-7 CAPLUS

CN 2-Furancarboxamide, N-(2,6-dichlorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-08-8 CAPLUS

CN 2-Furancarboxamide,

N-(4-bromo-2,6-dimethylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-09-9 CAPLUS CN 2-Furancarboxamide,

N-(2-chloro-4,6-dimethylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-10-2 CAPLUS

CN 2-Furancarboxamide, N-(3-chloro-2,6-diethylphenyl)-5-[(5,6,7,8-tetrahydro-

3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-11-3 CAPLUS

CN 2-Furancarboxamide, N-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

RN 263858-12-4 CAPLUS

CN 2-Furancarboxamide, N-(2-chloro-6-fluorophenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-13-5 CAPLUS

CN 2-Furancarboxamide,

N-(2,4-dichloro-6-methylphenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

RN 263858-14-6 CAPLUS

CN Benzoic acid, 2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)

Me Me Ph- 
$$(CH_2)_3$$
-O-C

 $CH_2$ 
 $CH$ 

RN 263858-15-7 CAPLUS
CN Benzoic acid, 2-[[[5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-2-furanyl]carbonyl]amino]-, hexyl ester (9CI) (CA INDEX NAME)

Me Me Me 
$$(CH_2)_{5-O-C}$$
 $CH_2$ 
 $C$ 

RN 263858-17-9 CAPLUS
CN 2-Furancarboxamide,
N-[2-[[[(2-fluorophenyl)methyl]amino]carbonyl]phenyl]5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl](9CI)
(CA INDEX NAME)

(CA INDEX NAME)

RN 263858-18-0 CAPLUS
CN 2-Furancarboxamide,
N-[2-[[(1-naphthalenylmethyl)amino]carbonyl]phenyl]-5[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI)

RN 263858-20-4 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]phen yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263858-21-5 CAPLUS

CN 2-Furancarboxamide,

N-[2-[[[(3,5-dichlorophenyl)methyl]amino]carbonyl]phen yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-(9CI) (CA INDEX NAME)

RN 263858-22-6 CAPLUS
CN 2-Furancarboxamide,
N-[2-[[[(2,5-dichlorophenyl)methyl]amino]carbonyl]phen
 yl]-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl] (9CI) (CA INDEX NAME)

Page 306 09763216.trn

RN 263858-24-8 CAPLUS

2-Furancarboxamide, N-(4-cyano-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-CN 3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

ANSWER 7 OF 26 CAPLUS COPYRIGHT 2002 ACS 1991:165135 CAPLUS

ACCESSION NUMBER:

DOCUMENT NUMBER: 114:165135

TITLE: Manufacture of divalent furan residue-containing

polyacylsemicarbazides

INVENTOR(S): Nowakowski, Jerzy

PATENT ASSIGNEE(S): Uniwersytet Mikolaja Kopernika, Pol.

SOURCE: Pol., 5 pp.

CODEN: POXXA7 DOCUMENT TYPE: Patent

LANGUAGE:

Polish

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND APPLICATION NO. DATE DATE PL 148406 В1 19891031 PL 1986-262913 19861209

GI

$$\begin{array}{c|c} - & & \\ - & &$$

AB The title polymers, having repeating units I (R = CH2, CH2CH2, 4-O2NC6H4CH; R1 = hexamethylene, 2,4-toluene, 4,4'-diphenylenemethane; N

d.p.), are prepd. by the polycondensation of dihydrazides II with diisocyanates OCNR1NCO in an inert org. solvent (e.g., DMSO) and under N at 293-343 K. I are useful for coatings and binders, esp. for the finishing treatment of wool fabrics (no data). Thus, a soln. of bis(5-hydrazinocarbonyl-2-furyl)methane in DMSO was mixed with 2,4-toluidinediisocyanate at a 1:1 mol ratio to give a title polyether-polyhydrazide-polysemicarbazide.

IT 125925-27-1P 125925-28-2P 125925-29-3P 125926-12-7P 125926-13-8P

RL: IMF (Industrial manufacture); PREP (Preparation) (manuf. of, for coatings and binders and wool fiber finishes)

RN 125925-27-1 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide, polymer with 1,6-diisocyanatohexane (9CI) (CA INDEX NAME)

CM 1

CRN 113423-66-8 CMF C17 H15 N5 O6

CM 2

CRN 822-06-0 CMF C8 H12 N2 O2

OCN-(CH<sub>2</sub>)<sub>6</sub>-NCO

RN 125925-28-2 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide, polymer with 2,4-diisocyanato-1-methylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 113423-66-8 CMF C17 H15 N5 O6

CM 2

CRN 584-84-9 CMF C9 H6 N2 O2

RN 125925-29-3 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide, polymer with 1,1'-methylenebis[4-isocyanatobenzene] (9CI) (CA INDEX NAME)

CM 1

CRN 113423-66-8 CMF C17 H15 N5 O6

CM 2

CRN 101-68-8 CMF C15 H10 N2 O2

RN 125926-12-7 CAPLUS

CN Poly[2,5-furandiyl[(4-nitrophenyl)methylene]-2,5-

PAGE 1-A

PAGE 1-B

RN 125926-13-8 CAPLUS

CN Poly[2,5-furandiyl[(4-nitrophenyl)methylene]-2,5-furandiylcarbonylhydrazocarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonylhydrazocarbonyl] (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

IT 113423-66-8P

RL: PREP (Preparation)
 (prepn. of, as monomer)

RN 113423-66-8 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & & & \\
C &$$

ANSWER 8 OF 26 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1990:139935 CAPLUS

DOCUMENT NUMBER: 112:139935

TITLE: Synthesis and properties of new oligomeric

heterocyclic poly(1-acylsemicarbazides)

AUTHOR(S): Nowakowski, J.

CORPORATE SOURCE: Pol.

SOURCE: Plast. Massy (1989), (9), 91-4

CODEN: PLMSAI; ISSN: 0554-2901

DOCUMENT TYPE: Journal LANGUAGE: Russian

GI

AB Heterocyclic oligosemicarbazides [I; Z = CH2, CHCH3, CHC6H4NO2-p; Z1 = (CH2)6, tolylene, p-C6H4CH2C6H4-p] were prepd. by polymn. of furan-based dihydrazides) with diisocyanates in an aprotic org. solvent (DMSO) at 293-343.degree.. The I were colored, powd. substances with poor soly. in typical org. solvents but sol. in dipolar aprotic solvents and in mineral acids. The oligomers had low thermal stability, with thermal degrdn. beginning at 358-370.degree..

IT 125925-27-1P 125925-28-2P 125925-29-3P

125926-12-7P 125926-13-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (oligomeric, prepn. and properties of)

RN 125925-27-1 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide, polymer with 1,6-diisocyanatohexane (9CI) (CA INDEX NAME)

CM 1

CRN 113423-66-8 CMF C17 H15 N5 O6

CM 2

CRN 822-06-0 CMF C8 H12 N2 O2

OCN-(CH<sub>2</sub>)<sub>6</sub>-NCO

RN 125925-28-2 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide, polymer with 2,4-diisocyanato-1-methylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 113423-66-8 CMF C17 H15 N5 O6

CM 2

CRN 584-84-9 CMF C9 H6 N2 O2

RN 125925-29-3 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide, polymer with 1,1'-methylenebis[4-isocyanatobenzene] (9CI) (CA INDEX NAME)

CM 1

CRN 113423-66-8 CMF C17 H15 N5 O6

CM 2

CRN 101-68-8 CMF C15 H10 N2 O2

RN 125926-12-7 CAPLUS

CN Poly[2,5-furandiyl[(4-nitrophenyl)methylene]-2,5-

furandiylcarbonylhydrazocarbonylimino-1,6-hexanediyliminocarbonylhydrazoca
 rbonyl] (9CI) (CA INDEX NAME)

PAGE 1-A


PAGE 1-B

RN 125926-13-8 CAPLUS

CN Poly[2,5-furandiyl[(4-nitrophenyl)methylene]-2,5-furandiylcarbonylhydrazocarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonylhydrazocarbonyl] (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B



L5 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:514910 CAPLUS

DOCUMENT NUMBER: 111:114910

TITLE: Synthesis of cephalosporin R-sulfoxides and their

bactericidal properties

AUTHOR(S): Mndzhoyan, Sh. L.; Kramer, M. S.; Aleksanyan, M. V.;

Ter-Zakharyan, Yu. Z.; Kazaryan, E. V. ITOKh im. Mndzhoyana, Yerevan, USSR

CORPORATE SOURCE: ITOKh im. Mndzhoyana, Yerevan, USSR SOURCE: Khim.-Farm. Zh. (1988), 22(9), 1091-4

CODEN: KHFZAN; ISSN: 0023-1134

DOCUMENT TYPE: Journal LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 111:114910

GI

AB The title compds. I [R = substituted benzyl, substituted 1-phenyl-1-cycloalkyl, etc.] were prepd. by acylating 7-amino-3-deacetoxycephalosporanic acid R-sulfoxide by the mixed anhydride method. Some I were more effective against Staphylococcus than cephalexin.

IT 122348-07-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and bactericidal activity of)

RN 122348-07-6 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

7-[[[5-[(4-chlorophenyl)methyl]-2-furanyl]carbonyl]amino]-3-methyl-8-oxo-,

5-oxide, [5R-(5.alpha.,6.alpha.,7.beta.)]- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

ANSWER 10 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:131458 CAPLUS

DOCUMENT NUMBER: 108:131458

TITLE: Synthesis and properties of new difuryl aliphatic

dihydrazides, diacyl chlorides and diacyl azides

AUTHOR(S): Nowakowski, Jerzy

CORPORATE SOURCE: Inst. Chem., N. Copernicus Univ., Torun, PL-87-100,

Pol.

SOURCE: J. Prakt. Chem. (1987), 329(3), 539-44

CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 108:131458

GI

AB Reaction of difuryl diesters I (R = H, Me, 4-O2NC6H4; R1 = OMe) with N2H4 gave dihydrazides I (R1 = NHNH2). Reaction of diacids I (R = H, Me; R1 = OH) with SOC12 gave I (R1 = Cl), which reacted with NaN3 to give diacyl azides I (R = H, Me; R1 = N3) (II). Attempts to subject II to Curtius rearrangement were not successful.

IT 113423-66-8P

RN 113423-66-8 CAPLUS

CN 2-Furancarboxylic acid, 5,5'-[(4-nitrophenyl)methylene]bis-, dihydrazide (9CI) (CA INDEX NAME)

ANSWER 11 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1987:209427 CAPLUS

DOCUMENT NUMBER:

106:209427

TITLE:

Synthesis and insecticidal activity of lipophilic amides. Part 2: effect of heteroatom replacements and of introducing methyl groups in the pentadiene

system

AUTHOR(S):

Elliott, Michael; Farnham, Andrew W.; Janes, Norman

F.; Johnson, Diana M.; Pulman, David A.

CORPORATE SOURCE:

Dep. Insectic. Fungic., Rothamsted Exp. Stn.,

Harpenden/Hertfordshire, AL5 2JQ, UK Pestic. Sci. (1987), 18(3), 203-9

CODEN: PSSCBG; ISSN: 0031-613X

SOURCE:

DOCUMENT TYPE:

Journal

LANGUAGE: English

The toxicities and insecticidal activities of RCH:CHCH:CHCONHCH2CHMe2, where R = PhCO, PhO, BrCH2, PhOCH2, and PhNHCH2, PhCH2CH:CHCO2CH2CHMe2 [108331-85-7], the benzyl oxime of CHOCH: CHCONHCH2CHMe2 [108331-86-8], (E)-N-(2,2-dimethylpropyl)-6-phenyl-4,5-epoxyhexa-2-enamide [108331-74-4], N-(2-methylpropyl)-5-benzylfuroic acid amides and N-(2-methylpropyl)methyl-6-phenylhexadienamides were very low against the housefly and mustard beetle due to the corresponding substituents. Thus, introduction of a heteroatom or Me group in the pentadiene system lowers or abolishes the insecticidal activity.

ΤТ 108331-76-6P

> RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and insecticidal activity of, structure in relation to)

RN 108331-76-6 CAPLUS

CN 2-Furancarboxamide, N-(2-methylpropyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1986:424091 CAPLUS

DOCUMENT NUMBER: 105:24091

TITLE: Investigations in the field of semisynthetic

cephalosporins. I. Synthesis and antibacterial activity of some 7-substituted 3-methyl-3-cephem-4-

carboxylic acids

AUTHOR(S): Mndzhoyan, Sh. L.; Kramer, M. S.; Ter-Zakharyan, Yu.

Z.; Oganyan, Sh. G.

CORPORATE SOURCE: ITOKhim. Mndzhoyaha, Yerevan, USSR SOURCE: Khim.-Farm. Zh. (1986), 20(4), 446-50

CODEN: KHFZAN; ISSN: 0023-1134

DOCUMENT TYPE: Journal LANGUAGE: Russian

AB Twelve 7-substituted 3-methyl-2-cephem-4 carboxylic acid derivs. were prepd.; 7-aminodesocetoxycephalosporic acid (ADCK) was reacted with chloranhydride carboxylic acids. In a 2nd method with improved yield, ADCK was first reacted with hexamethyldisilane to give a trimethylsilyl deriv., followed by reaction with the chloranhydride carboxylic acids. The trimethylsilyl group was then removed by hydrolysis. Antibacterial activities (min. inhibitory concns.) were detd. against strains of Staphylococcus aureus and toxicities were detd. in mice. Five compds. displayed high antistaphylococcal activity with min. inhibitory concns.

of
7.8 .mu.g/mL. Mol. structure of the derivs. is discussed with regard to their biol. activities.

IT 102907-74-4P 102907-75-5P

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study); PREP (Preparation) (prepn. and antibacterial activity of)

RN 102907-74-4 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Ph O R R CO2H

same as vet

RN 102907-75-5 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

7-[[[5-[(4-chlorophenyl)methyl]-2-furanyl]carbonyl]amino]-3-methyl-8-oxo-, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

C1
$$0 \qquad H \qquad H \qquad S$$

$$0 \qquad 0 \qquad N \qquad Me$$

$$C0_2H$$

ANSWER 13 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:472124 CAPLUS

DOCUMENT NUMBER: 101:72124

TITLE: Spectral characteristics of ureides, thioureides,

isoselenoureides, and guanidines Aleksashin, Yu. V.; Brega, V. D.

AUTHOR(S): Aleksashin, Yu. V.; Brega, V. D. CORPORATE SOURCE: Sarat. Med. Inst., Saratov, USSR

SOURCE: Nukleofil'nye Reakts. Karbonil'nykh Soedin. (1982),

98-100. Editor(s): Kharchenko, V. G. Izd. Saratov

Univ.: Saratov, USSR.

CODEN: 510KA2 Conference

DOCUMENT TYPE: Conference LANGUAGE: Russian

GI

AB IR spectral frequencies and NMR chem. shifts were obtained for the title compds. I (R = H, Me, Et, PhCH2, halo, NO2; X = O, S, NH) and II (R = H, Me).

IT 91360-07-5

RL: PRP (Properties)
 (IR spectrum of)

RN 91360-07-5 CAPLUS

CN 2-Furancarboxamide, N-(aminocarbonyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1977:528029 CAPLUS

DOCUMENT NUMBER: 87:128029

TITLE: Relation of antibacterial activity and penicillinase

resistance to the chemical structure of some

furylpenicillins

AUTHOR(S): Ordukhanyan, A. A.; Landau, M. A.; Kabankin, A. S.;

Mndzhoyan, Sh. L.; Ter-Zakharyan, Yu. Z. Inst. Tonkoi Org. Khim., Yerevan, USSR Khim.-Farm. Zh. (1977), 11(6), 37-41

CODEN: KHFZAN

DOCUMENT TYPE:

CORPORATE SOURCE:

LANGUAGE:

SOURCE:

Journal Russian

GΙ

AB Math. calcns. and exptl. studies using Staphylococcus aureus on 44 furylpenicillins indicated the resistance to penicillinase [9001-74-5] and

the bacteriostatic activity of the penicillin derivs. were increased by adherence to 4 structural criteria: substitution of a furan ring for a tetrahydrofuran, inclusion of compact substituents with high Chance .pi.-const. values, use of highly electroneg. substituents on the furan ring at the position nonadjacent to the O atom or to the side chain linking the furan ring to the penicillin moiety, and insertion of an isobutylnaphthalene moiety in the side chain. The most active compd. was I [63860-65-1].

IT 31336-55-7

RL: PRP (Properties)

(antibacterial activity and penicillinase resistance of)

RN 31336-55-7 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,

3,3-dimethyl-7-oxo-6-

[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

sent as forevious

Na

L5 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1977:406897 CAPLUS

DOCUMENT NUMBER: 87:6897

TITLE: N-(Benzimidazol-2-yl)arylcarboxamides as ultraviolet

light absorbers

INVENTOR(S): Grier, Nathaniel

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: U.S., 12 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4011236	А	19770308	US 1975-580847	19750527
US 3907700	Α	19750923	US 1973-320231	19730102
PRIORITY APPLN.	INFO.:		US 1968-758601	19680909
			US 1973-320231	19730102

GI

AB N-(Benzimidazol-2-yl)arylcarboxamides (I, R1 = arom. radical with 1-3 nuclei, ring-substituted arom. radical, arom. heterocyclic radical; R2 = H, Me, aliph. or arom. acyl) were prepd. by condensing an aminobenzimidazole with an arom. acid halide. These compns. are useful as

UV light absorbers in plastics, fibers, sun tan lotions, etc. Thus, p-tert-butylbenzoic acid [98-73-7] was chlorinated with thionyl chloride to give p-tert-butylbenzoyl chloride [1710-98-1], which was condensed with

2-aminobenzimidazole [934-32-7] to give N-(benzimidazol-2-yl)-4-tertbutylbenzamide (I, R1 = 4-tert-butylphenyl, R2 = H) [25737-69-3].

IT 27111-39-3P

RL: PREP (Preparation)

(prepn. of, for light stabilizers)

27111-39-3 CAPLUS RN

2-Furancarboxamide, N-1H-benzimidazol-2-yl-5-benzoyl- (9CI) (CA INDEX CN NAME)

$$\begin{array}{c|c}
H & O & O \\
N & NH - C & O & C - Ph
\end{array}$$

ANSWER 16 OF 26 CAPLUS COPYRIGHT 2002 ACS

CESSION NUMBER: 1976:4959 CAPLUS

DOCUMENT NUMBER: 84:4959

TITLE: Control of uv deterioration by incorporation of

N-(benzimidazol-2-yl) arylcarboxamides into a uv

sensitive substance

Grier, Nathaniel INVENTOR(S):

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

U.S., 14 pp. SOURCE: CODEN: USXXAM

Patent

DOCUMENT TYPE: LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3907700	А	19750923	US 1973-320231	19730102
NL 6913261	A	19700311	NL 1969-13261	19690829
GB 1287955	A	19720906	GB 1969-29264	19690904
GB 1287954	A	19720906	GB 1969-43800	19690904
BE 738534	A	19700309	BE 1969-738534	19690908
FR 2017676	A5	19700522	FR 1969-30666	19690909
CH 555387	A	19741031	CH 1969-13630	19690909
US 4011236	A	19770308	US 1975-580847	19750527
PRIORITY APPLN. I	NFO.:		US 1968-758601	19680909
			US 1973-320231	19730102

For diagram(s), see printed CA Issue. GΙ

Amides  $\tilde{I}$  (R = C6H4CMe3-4, 4-thiazolyl, 2-thienyl, 5-tert-butyl-2-furyl, C6H4CO2Bu-2, C6H4CO2Et-4, 4- or 3-(2-benzimidazolylaminocarbonyl)phenyl, AΒ N-(2-benzimidazolyl) phthalimid-4-yl, R1 = H; R = Ph, R1 = 4-Me; R = 2-furyl, R1 = 5-C1) were prepd. by acylating the 2-aminobenzimidazoles.

are uv absorbers for plastics and sunscreens.

ΙT 27111-39-3P

Ι

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 27111-39-3 CAPLUS

CN 2-Furancarboxamide, N-1H-benzimidazol-2-yl-5-benzoyl- (9CI) (CA INDEX NAME)

L5 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:563755 CAPLUS

DOCUMENT NUMBER: 77:163755

TITLE: Acid resistance of 2-furyl, 2-furylethenyl, and

.beta.-(2-furyl)-.beta.'-(.alpha.-

naphthyl)isopropylpenicillins

AUTHOR(S): Ter-Zakharyan, Yu. Z.; Oganyan, Sh. G.

CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyana, Erevan, USSR

SOURCE: Biol. Zh. Arm. (1972), 25(5), 81-4

CODEN: BZARAZ

DOCUMENT TYPE: Journal LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB Half-lives for the decompn. of 18 penicillin derivs. [I, R = 5-R1-substituted-2-furyl or -2-furylvinyl, .beta.-(5-R1-substituted-2-furyl)-.beta.'-(1-naphthyl)isopropyl (R1 = H, Me, Et, Br, PhCH2, p-MeOC6H4CH2, veratryl, etc.)] were detd. in aq. HCl at pH 1.3 and 37.degree.. Factors increasing the stability of these penicillins (compared with benzylpenicillins) were: electron-accepting groups on the furan ring and steric effects of the substituted isopropyl derivs. I (R

2-furylvinyl) were more stable than I (R = 2-furyl).

IT 29876-13-9 31302-57-5 31336-55-7

RL: PRP (Properties)

(stability of, to hydrochloric acid)

RN 29876-13-9 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[5-[(4-methoxyphenyl)methyl]-2-furanyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Na

RN 31302-57-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[5-[(3,4-dimethoxyphenyl)methyl]-2-furanyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Na

RN 31336-55-7 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, monosodium salt,
[2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Na

L5 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:30833 CAPLUS

DOCUMENT NUMBER: 76:30833

TITLE: Chemical structure dependence of the biological

action

of some acyl derivatives of 6-propionic acid amide

AUTHOR(S): Mndzhoyan, A. L.; Ter-Zakharyan, Yu. Z.; Oganyan, Sh.

G.

CORPORATE SOURCE: USSR

SOURCE: Polusin. Penitsilliny (1969) 38-9

From: Ref. Zh., Biol. Khim. 1971, Abstr. No. 2F880

DOCUMENT TYPE: Journal LANGUAGE: Russian

AB The antibacterial activity, acute toxicity, and penicillinase resistance of 38 semisynthetic penicillins, such as phenylpenicillin (I)

[6489-59-4],

o-methoxyphenylpenicillin [26994-40-1], 3-methoxy-4alkoxyphenylpenicillins, 3-methoxy-4-alkoxybenzylpenicillins, substituted furylpenicillin, and alkoxyphenylcyclopentylpenicillin were studied. The antibacterial spectrum of the studied substances was similar to that of benzylpenicillin [61-33-6], but the latter had much stronger action against the causative strains sensitive to it. Substitution of the PhCH2 radical for Ph led to a decrease in antimicrobial activity and in this case o-, m-, and p-methoxyphenylpenicillins were more active than I. Substitution of Ph at the furyl group increased the antibacterial action. (5-Ethylfuryl)penicillin [28816-57-1], (5-benzylfuryl)penicillin [ 28816-59-3], and also 4,5-substituted furylpenicillins contg. Meand PhCH2 radicals were active against gram-pos. bacteria; however, introducing N-contg. substituents (morpholine [110-91-8], piperidine [110-89-4], pyrrolidine [123-75-1]) into position 4 or 4 and 5 of the furan ring led to a complete loss of penicillin activity.

Dimethylfurylpenicillin [28816-66-2] and penicillin contg. a cyclopentyl group in a side chain possessed high penicillinase resistance. P-alkoxyphenylcyclopentylpenicillins suppressed the growth of microbes resistant to benzylpenicillin. All synthesized penicillins except furylpenicillins were slightly toxic. Furylpenicillins, mainly 4 and

5-Ph


substituted, possessed an increased toxicity.

IT 28816-59-3

RL: PRP (Properties)

(bacterial resistance to, penicillinase in relation to)
RN 28816-59-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6 [[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1971:550291 CAPLUS

DOCUMENT NUMBER: 75:150291

TITLE: Induction of staphylococcal penicillinase synthesis

by

semisynthetic penicillins of the furan series

AUTHOR(S): Ter-Zakharyan, Yu. Z.; Oganyan, Sh. G.

CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyan, Erevan, USSR

SOURCE: Biol. Zh. Arm. (1971), 24(7), 21-5

CODEN: BZARAZ

DOCUMENT TYPE: Journal LANGUAGE: Russian

AB The penicillinase synthesis in Staphylococcus induced by semisynthetic penicillins of the furan series was detd. by an iodometric method.

Bacteria, .apprx.5.times.108 cells/ml, were incubated 0-6 hr at

27.degree.

in the presence of the antibiotics, 0-500 units/ml. The highest penicillinase activity was obsd. in cells incubated in the presence of benzylfurylpenicillin. Max. penicillinase activity was obsd. after 4 hr incubation of cells with inductor.

IT **31336-55-7** 

RL: BIOL (Biological study)

(penicillinase induction by, in Staphylococcus)

RN 31336-55-7 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,

3,3-dimethyl-7-oxo-6-

[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, monosodium salt,

[2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Na

L5 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1971:71908 CAPLUS

DOCUMENT NUMBER: 74:71908

TITLE: Reaction of penicillinases with 6-aminopenicillanic

derivatives of furan-2-carboxylic and furyl-2-acrylic

acids

AUTHOR(S): Ter-Zakharyan, Yu. Z.; Oganyan, Sh. G. CORPORATE SOURCE: Inst. Fine Org. Chem., Erevan, USSR

SOURCE: Antibiotiki (Moscow) (1971), 16(1), 11-14

CODEN: ANTBAL

DOCUMENT TYPE: Journal LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB (5-Ethyl-2-furyl)penicillin (I), [5-(p-methoxybenzyl)-2-furyl]penicillin, and 7 other derivs. of 2-furylpenicillin were approx. as sensitive as 2-furylpenicillin to the penicillinases of staphylococci and Bacillus cereus, but showed greater resistance to the penicillinases from Escherichia coli, Bacillus licheniformis, and Klebsiella aerogenes [Enterobacter aerogenes]. [3-(5-Benzyl-2-furyl)acrylo]penicillin (II)

and

other aromatic derivs. of [3-(2-furyl)-acryloyl]penicillin were more resistant to these enzymes than was benzylpenicillin.

IT 29876-13-9 31302-57-5 31336-55-7

31444-61-8

RL: RCT (Reactant)

(hydrolysis of, by penicillinase)

RN 29876-13-9 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[5-[(4-methoxyphenyl)methyl]-2-furanyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Na

RN 31302-57-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[5-[(3,4-dimethoxyphenyl)methyl]-2-furanyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Na

RN 31336-55-7 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-7-oxo-6[[[5-(phenylmethyl)-2-furanyl]carbonyllaminol-\_monosodium\_salt

[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, monosodium salt,
[2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Na

RN 31444-61-8 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(5-benzoyl-2-furamido)-3,3-dimethyl-7-oxo-, monosodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.

Na

L5 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1970:487832 CAPLUS

DOCUMENT NUMBER: 73:87832

TITLE: Semisynthetic penicillins. IV. 6-Aminopenicillanic

derivatives of 5- and 4,5-substituted

furan-2-carboxylic and furyl-2-acrylic acids

AUTHOR(S): Mndzhoyan, A. L.; Tsinker, M. G.; Mkrtchyan, E. S.;

Ter-Zakharyan, Yu. Z.; Oganyan, Sh. G.

CORPORATE SOURCE: Inst. Tonkoi Org. Khim., Erevan, USSR SOURCE: Khim.-Farm. Zh. (1970), 4(5), 15-21

CODEN: KHFZAN

DOCUMENT TYPE: Journal LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB A series of the title compds. (I-II) was prepd. and pharmacol. tested. Thus, 6-aminopenicillanic acid was treated with Me furan-2-carboxylates

at

pH 7 or treated with acid chlorides to give the following penicillins

[R1,

R2, % yield, m.p., and [.alpha.]20D (H2O) given]: I: H, H, 64.6, 97-8.degree., 185.9.degree.; Br, H, 81.1, 109-10.degree., 157.4.degree.;

```
Me, H, 69.8, 81-2.degree., 220.3.degree.; Et, H, 65.4, 113-14.degree.,
     159.4.degree.; PrOCH2, H, 72.3, 84-5.degree., 159.4.degree.; PhCH2, H,
     69.1, 93-4.degree., 200.2.degree.; 4-MeOC6H4CH2, H, 74.3, 79-80.degree.,
     185.9.degree.; 3,4-(MeO)2C6H3CH2, H, 73.6, 102-3.degree., 185.9.degree.;
     4-MeC6H4CH2, H, 81.2, 105-6.degree., 159.4.degree.; morpholinomethyl (M),
     H, 46.5, 134-5.degree., 188.9.degree.; piperidinomethyl (N), H, 48.3,
     118-19.degree., 220.3.degree.; pyrrolidinomethyl (P), H, 47.5,
     110-11.degree., 185.9.degree.; Me, Me, 78.5, 145-6.degree.,
185.9.degree.;
    Me, PhCH2, 88.9, 88-9.degree., 250.3.degree.; Me, M, 45.2, 143-4.degree.,
     220.3.degree.; Me, N, 47.9, 130-31.degree., 188.9.degree.; Me, P, 44.7,
     120-21.degree., 220.3.degree.; II: H, H, 85.1, 132-3.degree.,
     220.3.degree.; Me, H, 82.4, 118-19.degree., 280.5.degree.; Et, H, 82.3,
     108-9.degree., 238.2.degree.; PhCH2, H, 86.2, 88-9.degree.,
210.7.degree.;
     4-MeC6H4CH2, H, 87.7, 101-2.degree., 264.7.degree.; 4-MeOC6H4CH2, H,
79.3,
     110-12.degree., 243.5.degree.; Me, Me, 84.2, 95-6.degree., 291.1.degree.;
    Me, PhCH2 (III), 76.3, 85-6.degree., 243.5.degree.. Antibacterial data
of
     I and II are given as well as their stabilities against acid hydrolysis
     and penicillinase. Compared with benzylpenicillin, III is more stable
     against penicillinase, more acid resistant and active against gram-pos.
    bacteria.
     28816-59-3P 28816-60-6P 28816-61-7P
TΤ
     28816-62-8P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of)
     28816-59-3 CAPLUS
RN
     4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
CN
3,3-dimethyl-7-oxo-6-
     [[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]-, [2S-
     (2.alpha., 5.alpha., 6.beta.)] - (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.


RN 28816-60-6 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[5-(p-methoxybenzyl)-2-furamido]-3,3-dimethyl-7-oxo- (8CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 28816-62-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
3,3-dimethyl-6-[5-(pmethylbenzyl)-2-furamido]-7-oxo- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1970:132730 CAPLUS

DOCUMENT NUMBER:

72:132730

TITLE:

Ultraviolet-absorbing

N-(2-benzimidazolyl)carboxamides

INVENTOR(S):

Grier, Nathaniel

PATENT ASSIGNEE(S): Merck and Co., Inc. SOURCE: Ger. Offen., 50 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

DE 1945452 19700319

PRIORITY APPLN. INFO.: US 19680909

GI For diagram(s), see printed CA Issue.

The title compds., absorbing at 300-50 m.mu., were prepd. Thus, 15.7 gAΒ p-tert-BuC6H4COC1, b2.2 100.degree., formed from the acid and SOC12, and 10.7 g 2-aminobenzimidazole (I) in 100 ml pyridine were hea ted 1.5 hr to give 22.5 g II (R = p-tert-BuC6H4, R1 = H), m. 246-8.degree.. Similarly prepd. were II (R, R1, and m.p. given): 4-thiazolyl, H. 294-6.degree.; 2-benzofuryl, H, 293-4.degree.; 3-pyridyl, H, -; 2-furyl, Cl, 250-1.degree.; .beta.-(2-furyl) vinyl, H, 250-1.degree.; 5-tert-butyl-2-furyl, H, 257.5-9.degree.; 5-phenyl-2-furyl, H, 247-8.5.degree.; 5-benzoyl-2-furyl, H, 268-71.degree.; 4-Et02CC6H4, H, 224-5.5.degree.; and III (Y= m-phenylene), m. >320.degree.; III (Y = p-phenylene), m.>340.degree.;  $\overline{IV}$  ( $\overline{R2}$  = H) ( $\overline{IVa}$ ), m. 266-8.degree., and  $\overline{IV}$ (R2 = 2-benzimidazolylaminocarbonyl), m. 352-3.degree.. IVa (4 g) in 200ml BuOH was heated 35 min at 115.degree. to give 2.5 g II (R = .omicron.-BuO2CC6H4, R1 = H), m. 187.degree.. 2-Thenoyl chloride (0.04 mole) in 15 ml HCONMe2 was added to 0.02 mol e H2NC(SMe):NH.H2SO4 and 0.04

mole Et3N in 50 ml HCONMe 2 at 0.degree. and stirred 2 hr at room temp.

give V, m. 166-7.degree.. V (0.01 mole) and 1.08 g .omicron.phenylenediamine in 50 ml EtOH was refluxed 5 hr to give II (R =
2-thienyl, R1 = H), m. 303-5.degree.. They can be incorporated into
plastics to protect them against the discoloration, impairment of tensile
strength, or embrittlement. They can be added directly to dyes,
plasticizers, antimicrobial agents, insect repellents, sun tan lotions,

skin creams and can be used for textiles, in varnishes for wood, masonry, and metals, in plastic packages for foods, and in hair creams.

IT 27111-39-3P

RN 27111-39-3 CAPLUS

or

CN 2-Furancarboxamide, N-1H-benzimidazol-2-yl-5-benzoyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
H & O & O \\
N & NH - C & O & C - Ph
\end{array}$$

```
ANSWER 23 OF 26 CAPLUS COPYRIGHT 2002 ACS
                          1970:100448 CAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                          72:100448
TITLE:
                          Furan derivatives. XXXVIII. Hydrazidohydrazones of
                          the pyridine and furan series
AUTHOR(S):
                          Mndzhoyan. A. L.; Afrikyan, V. G.; Oganesyan, R. S.;
                          Adzhibekyan, A. S.; Karagezyan, S. G.; Sarafyan, V.
CORPORATE SOURCE:
                          Inst. Tonkoi Org. Khim., Erevan, USSR
                          Arm. Khim. Zh. (1969), 22(10), 922-32
SOURCE:
                          CODEN: AYKZAN
DOCUMENT TYPE:
                          Journal
LANGUAGE:
                          Russian
GI
     For diagram(s), see printed CA Issue.
AB
     A new series of title compds. was prepd. as potential chemotherapeutic
     agents for tuberculosis. To increase water soly. of the formerly prepd.
     analogs (CA 70: 1153 u; 67: 53943z), a new series (I) contg.
     morpholinlomethyl (Q), piperidinomethyl (T), and pyrrolidinomethyl (Y)
     groups was obtained. R, R1, pyridyl ring, substitution position, %
yield,
     and m.p. for I were as follows: Q, H, 2, 73, 150-1.degree.; Q, H, 3, 70,
     142-4.degree.; Q, H, 4, 75.4, 157-8.degree.; T, H, 2, 70, 146-8.degree.;
     T, H, 3, 93, 161-2.degree.; T, H, 4, 93, 168-9.degree.; Y, H, 2, 92.7,
     141-2.degree.; Y, H, 3, 96, 109-10.degree.; Y, H, 4, 92, 135-6.degree.;
     3,4-(MeO)2C6H3CH2 (Z), H, 2, 89.7, 140-1.degree.; Z, H, 3, 88,
     153-4.degree.; Z, H, 4, 84.6, 226-7.degree.; Me, Q, 2, 90,
112-13.degree.;
     Me, Q, 3, 92, 109-10.degree.; Me, Q, 4, 91, 125-6.degree.; Me, T, 2, 89,
     106-7.degree.; Me, T, 3, 92, 127-8.degree.; Me, T, 4, 92.2,
     117-18.degree.; Me, Y, 2, 92, 114-15.degree.; Me, Y, B, 93,
     111-12.degree.; and Me, Y, 4, 91.7, 100-1.degree.. II were also prepd. (same data given): Z, H, 2, 81.6, 187-8.degree.; Z, H, 3, 87.5, 181-2.degree.; Z, H, 4, 82, 158-9.degree.; Z, Me, 2, 87.6,
148-50.degree.;
     Z, Me, 3, 81, 145-6.degree.; and Z, Me, 4, 89, 151-2.degree.. In III,
the
     substitution position of the pyridyl rings, % yield, and m.p. were: 2,
     92.3, 248-9.degree.; 3, 91, 300-1.degree.; and 4, 93.8, 305-6.degree..
     Bactericidal potencies of the compds. against 8 tuberculosis lab.
strains,
     in vitro, were low, except for 4 more active II with 2 and 4-pyridine
     orientation. Data on potencies and LD (for mice) of I, II, and III are
     given. I were 5-10 times more potent against a resistant strain, freshly
     obtained from patients, than against lab. strain. Phys. consts. of the
     intermediate furans were given. Prepns. were by conventional methods.
ΙT
     26095-25-0P 26095-26-1P 26095-27-2P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of)
     26095-25-0 CAPLUS
     2-Furoic acid, 5-veratryl-, (2-pyridylmethylene)hydrazide (8CI)
INDEX
     NAME)
```

Page 334 09763216.trn

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

26095-26-1 CAPLUS RN

CN 2-Furoic acid, 5-veratryl-, (3-pyridylmethylene)hydrazide (8CI) (CA INDEX

NAME)

26095-27-2 CAPLUS RN

CN 2-Furoic acid, 5-veratryl-, (4-pyridylmethylene)hydrazide (8CI) INDEX

NAME)

$$\begin{array}{c|c} & & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

ANSWER 24 OF 26 CAPLUS COPYRIGHT 2002 ACS

1970:21544 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 72:21544

TITLE: Furan derivatives. XXXVII. Aminoamides of

5-substituted furan-2-carboxylic acids

Mndzhoyan, A. L.; Akopyan, T. R.; Sanasaryan, A. A.; Kolotyan, L. A.; Asratyan, S. N. AUTHOR(S):

CORPORATE SOURCE: Inst. Tonkoi Org. Khim., Erevan, USSR

Arm. Khim. Zh. (1969), 22(9), 826-9 SOURCE: CODEN: AYKZAN

DOCUMENT TYPE: Journal LANGUAGE: Russian

For diagram(s), see printed CA Issue. GΙ

To 0.1 mole 5-substituted-furan-2-carbonyl chloride in 100 ml C6H6 was ΑB added dropwise 0.2 mole (dialkylamino)alkylamine in 100 ml. C6H6 to gi ve the following I (R, R', n, % yield, b.p./mm, d20, and n20D given): Me,

Me,

```
2, 80.0, 185-6.degree./1.6, 1.0699, 1.5229; Me, Et, 2, 81.0,
    190-1.degree./1.5, 1.0379, 1.5138; Me, Me, 3, 81.5, 198-200.degree./1.5,
    1.0523, 1.5182; Me, Et, 3, 80.0, 209-10.degree./1.4, 1.0216, 1.5092; Et,
    Me, 2, 84.8, 194-5.degree./1.5, -, -; Et, Et, 2, 94.0, 201-2.degree./1.5,
    1.0148, 1.5078; Et, Me, 3, 88.6,210-12.degree./1.5, 1.0399, 1.5120; Et,
    Et, 3, 86.4, 218-20.degree./1.5, 1.0314, 1.5058; PhCH2, Me, 2, 92.1,
    219-21.degree./1.5, -, -; PhCH2, Et, 2, 91.5, 238-9.degree./1.5, 1.0643,
    1.5470; PhCH2, Me, 3, 93.0, 229-30.degree./1.5, -, -; PhCH2, Et, 3, 90.9,
    249-50.degree./-1.5, 1.0584, 1.5470; p-MeC6H4CH2, Me, 2, 80.5,
    237-8.degree./1.5, 1.0839, 1.5597; p-MeC6H4CH2, Et, 2, 82.9,
    243-5.degree./1.4, 1.0549, 1.5478; p-MeC6H4CH2, Me, 3, 83.0,
    254-5.degree./1.4, 1.0993, 1.5501; p-MeC6H4CH2, Et, 3, 77.1,
    262-3.degree./1.1, 1.0531, 1.5443; p-Me-OC6H4CH2, Me, 2, 86.8,
    230-3.degree./1, -, -; p-MeOC6H4CH2, Et, 2, 82.9, 235-6.degree./1.5, -,
    p-MeOC6H4CH2, Me, 3, 93.5, 237-8.degree./1.5, -, -; p-MeOC6H4CH2, Et, 3,
    86.0, 254-5.degree./1.5, -, -. I were converted to sol. salts for
    pharmacol. studies; the hydrochlorides and alkyl iodides in most cases
are
    noncryst. oils. I salts have temporary hypotensive activities. The
    methiodide diethylaminoethylamide of 5-benzylfuran-2-carboxylic acid r
     e-duces the blood pressure 25-30 mm in an hr at 2 mg/kg dose.
    24451-75-0P 24451-76-1P 24451-77-2P
IT
    24451-78-3P 24451-79-4P 24451-80-7P
    24451-81-8P 24451-82-9P 24451-83-0P
    24451-84-1P 24451-85-2P 24451-86-3P
    RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of)
     24451-75-0 CAPLUS
RN
     2-Furamide, 5-benzyl-N-[2-(dimethylamino)ethyl]- (8CI) (CA INDEX NAME)
CN
```

$$\mathsf{Ph}\!-\!\mathsf{CH}_2 \underbrace{\hspace{1cm} \overset{\mathsf{O}}{\underset{\mathsf{C}^-}{\mathsf{NH}^-}} \mathsf{CH}_2\!-\!\mathsf{CH}_2\!-\!\mathsf{NMe}_2}^{\mathsf{O}}$$

RN 24451-76-1 CAPLUS CN 2-Furamide, 5-benzyl-N-[2-(diethylamino)ethyl]- (8CI) (CA INDEX NAME)

$$Ph-CH_2 \underbrace{\hspace{1cm} \overset{O}{||}_{C-NH-CH_2-CH_2-NEt_2}^{O}}_{C-NH-CH_2-CH_2-NEt_2}$$

RN 24451-77-2 CAPLUS CN 2-Furamide, 5-benzyl-N-[3-(dimethylamino)propyl]- (8CI) (CA INDEX NAME)

$$^{\text{Ph-CH}_2}$$
  $^{\text{O}}$   $^{\text{C-NH-(CH}_2)}$   $^{3-\text{NMe}_2}$ 

RN 24451-78-3 CAPLUS

CN 2-Furamide, 5-benzyl-N-[3-(diethylamino)propyl]- (8CI) (CA INDEX NAME)

RN 24451-79-4 CAPLUS

CN 2-Furamide, N-[2-(dimethylamino)ethyl]-5-(p-methylbenzyl)- (8CI) (CA INDEX NAME)

$$\mathsf{Me_2N-CH_2-CH_2-NH-C} \overset{\mathsf{O}}{\longrightarrow} \mathsf{CH_2} \overset{\mathsf{O}}{\longrightarrow} \mathsf{CH_2} \overset{\mathsf{O}}{\longrightarrow} \mathsf{Me}$$

RN 24451-80-7 CAPLUS

CN 2-Furamide, N-[2-(diethylamino)ethyl]-5-(p-methylbenzyl)-(8CI) (CA INDEX

NAME)

$$\mathsf{Et_2N-CH_2-CH_2-NH-C} \overset{\mathsf{O}}{\longrightarrow} \mathsf{CH_2-CH_2-NH-C} \overset{\mathsf{O}}{\longrightarrow} \mathsf{CH_2-C$$

RN 24451-81-8 CAPLUS

CN 2-Furamide, N-[3-(dimethylamino)propyl]-5-(p-methylbenzyl)- (8CI) (CA INDEX NAME)

$$Me_2N-(CH_2)_3-NH-C$$

O

 $CH_2$ 

Me

RN 24451-82-9 CAPLUS

CN 2-Furamide, N-[3-(diethylamino)propyl]-5-(p-methylbenzyl)- (8CI) (CA INDEX NAME)

RN 24451-83-0 CAPLUS

CN 2-Furamide, N-[2-(dimethylamino)ethyl]-5-(p-methoxybenzyl)- (8CI) (CA INDEX NAME)

RN 24451-84-1 CAPLUS

CN 2-Furamide, N-[2-(diethylamino)ethyl]-5-(p-methoxybenzyl)- (8CI) (CA INDEX NAME)

$$\operatorname{Et}_{2}\operatorname{N}-\operatorname{CH}_{2}-\operatorname{CH}_{2}-\operatorname{NH}-\operatorname{C}$$
 O  $\operatorname{CH}_{2}$   $\operatorname{CH}_{2}$  OMe

RN 24451-85-2 CAPLUS

CN 2-Furamide, N-[3-(dimethylamino)propyl]-5-(p-methoxybenzyl)- (8CI) (CA INDEX NAME)

24451-86-3 CAPLUS RN

CN 2-Furamide, N-[3-(diethylamino)propyl]-5-(p-methoxybenzyl)- (8CI) INDEX NAME)

$$Et_2N-(CH_2)_3-NH-C$$

O

CH2

OMe

ANSWER 25 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1969:11530 CAPLUS

DOCUMENT NUMBER:

70:11530

TITLE:

Furan derivatives. XXXIII. .alpha.-, .beta.-, and .gamma.-Pyridinecarboxaldehyde 5-and 4,5-substituted

furoylhydrazones

AUTHOR(S):

Mndzhoyan, A. L.; Afrikyan, V. G.; Oganesyan, R. S.; Shakhmuradova, A. O.; Zhuruli, L. D.; Karagezyan, S.

G.; Sarafyan, V. G.

CORPORATE SOURCE:

SOURCE:

Inst. Tonkoi Org. Khim., Erevan, USSR Arm. Khim. Zh. (1968), 21(4), 340-7

CODEN: AYKZAN

DOCUMENT TYPE:

Journal Russian

LANGUAGE:

GΙ For diagram(s), see printed CA Issue.

The following hydrazides (I) of 5- and 4.5-substituted furan-2-carboxylic acids were prepd. by boiling 0.1 mole of an alkyl ester of the acid with AB 0.12 mole N2H4.H2O in abs. EtOH for 10 hrs. (R, R', % yield, and m.p. given): Me, H, 96.1, 59-60.degree.; Et, H, 78.0, 68-70.degree.; PhCH2, H, 91.1, 98-9.degree.; MeC6H4CH2, H, 94, 104-5.degree.; MeOC6H4CH2, H, 88.1, 80-2.degree.; Me, Me, 80.0, 95-6.degree.; Me, PhCH2, 79.5, 109-10.degree..

Treatment of 0.1 mole I with 0.11 mole .alpha.-, .beta.- and .gamma.-pyridine-carboxaldehyde, resp., in abs. EtOH yielded the following

II R, R1, orientation of pyridine ring, % yield, and m.p. given): Me, H, .alpha., 78.8, 178-9.degree.; Me, H, .beta., 91.3, 129-30.degree.; Me, H, .gamma., 89.9, 150-1.degree.; Et, H, .alpha., 75.8, 138-9.degree.; Et, H, .beta., 90.9, 163-4.degree.; Et, H, .gamma., 89.8, 115-16.degree.; PhCH2, H, .alpha., 89.3, 164-5.degree.; PhCH2, H, .beta., 95.5, 195-6.degree.; PhCH2, H, .gamma., 95.3, 175-6.degree.; MeC6H4CH2, H, .alpha., 68.4, 135-7.degree.; MeC6H4CH2, H, .beta., 80.0, 155-6.degree.; MeC6H4CH2, H,

.gamma., 78.0, 176-8.degree.; MeOC6H4CH2, H, .alpha., 70.0, 164-5.degree.; MeOC6H4CH2, H, .beta., 60.4, 185-6.degree.; MeOC6H4CH2, H, .gamma., 75.5, 170-1.degree.; Me, Me, .alpha., 72.5, 189-90.degree.; Me, Me, .beta., 94.0, 180-2.degree.; Me, Me, .gamma., 83.0, 175-6.degree.; Me, PhCH2, .alpha., 75.6, 184-5.degree.; Me, PhCH2, .beta., 94.6, 162-3.degree.; Me, PhCH2, .gamma., 81.8, 180-1.degree.. Reaction of pyridinecarboxaldehydes with the hydrazides of pyridinecarboxylic acids generated the following III (orientation of acid, orientation of aldehyde, % yield, and m.p. given): .alpha., .alpha., 91.6, 158-9.degree.; .alpha., .beta., 90.6, 168-9.degree.; .alpha., .gamma., 74.8, 194-5.degree.; .beta., .alpha., 71.2, 158-9.degree.; .beta., .beta., 80.0, 206-7.degree.; .beta., .gamma., 68.6, 197-8.degree.; .gamma., .alpha., 70.1, 163-4.degree.; .gamma., .beta., 72.2, 233-4.degree.; .gamma., .gamma., 83.1, 227-9.degree.. IV were also prepd. (no chem. details given). All compds. were tested for tuberculostatic activity against several strains of organisms. Of all compds., those most generally effective were those members of groups III and IV which were derived from pyridine-2- and pyridine-4-carboxylic acid. ΙT 20842-20-0P 20842-21-1P 20842-30-2P 20842-31-3P 20842-32-4P 20842-33-5P 20842-34-6P 20842-35-7P

RN 20842-21-1 CAPLUS CN 2-Furoic acid, 5-(p-methoxybenzyl)-, hydrazide (8CI) (CA INDEX NAME)

RN 20842-30-2 CAPLUS
CN 2-Furoic acid, 5-benzyl-, (2-pyridylmethylene)hydrazide (8CI) (CA INDEX NAME)

RN 20842-31-3 CAPLUS

CN 2-Furoic acid, 5-benzyl-, (3-pyridylmethylene)hydrazide (8CI) (CA INDEX NAME)

RN 20842-32-4 CAPLUS

CN 2-Furoic acid, 5-benzyl-, (4-pyridylmethylene)hydrazide (8CI) (CA INDEX NAME)

RN 20842-33-5 CAPLUS

CN 2-Furoic acid, 5-(p-methoxybenzyl)-, (2-pyridylmethylene)hydrazide (8CI) (CA INDEX NAME)

$$CH_2$$
 $CH_2$ 
 $CH_2$ 

RN 20842-34-6 CAPLUS

CN 2-Furoic acid, 5-(p-methoxybenzyl)-, (3-pyridylmethylene)hydrazide (8CI) (CA INDEX NAME)

RN 20842-35-7 CAPLUS

CN 2-Furoic acid, 5-(p-methoxybenzyl)-, (4-pyridylmethylene)hydrazide (8CI) (CA INDEX NAME)

ANSWER 26 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1967:453943 CAPLUS

DOCUMENT NUMBER: 67:53943

TITLE: Furan derivatives. XXXI. Some acid 2-alkylidene

hydrazides and N, N'-diacylhydrazines as potential

antitubercular agents

AUTHOR(S): Mndzhoyan, A. L.; et al.

SOURCE: Arm. Khim. Zh. (1966), 19(10), 793-805

CODEN: AYKZAN

DOCUMENT TYPE: Journal LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

cf. CA 63: 18004h. The title compds. were synthesized to find active antitubercular agents. 4-Ethoxybenzyl chloride (I), bl 105.degree., was prepd. in 67.7% yield by chloromethylation of phenetole. To 40 g. Me furan-2-carboxylate in 50 ml. CS2 in the presence of 0.025 mole ZnCl2, 10 ml. I in 50 ml. CS2 was added dropwise with stirring at 0.degree. and the mixt. kept 30 min. at 0.degree. and 30 min. at room temp. to give Me 5-(p-ethoxybenzyl)furan-2-carboxylate. Similarly prepd. were the following II, (R1 = H, R2 = CO2Me) (R, % yield, b.p./mm., n20D, and d20 given): p-ClC6H4CH2, 61.3, 178-9.degree./3 (m. 36-7.degree.), -, -; p-MeOC6H4CH2, 50.5, 176-8.degree./3, 1.1704, 1.5588; p-EtOC6H4CH2, 46.8,

183-5.degree./3, 1.1475, 1.5475; p-PrOC6H4CH2 50.2, 189-90.degree./3, 1.1232, 1.5435; p-BuOC6H4CH2, 51.5, 196-8.degree./3, 1.1184, 1.5420; p-AmOC6H4CH2, 49.2, 210-11.degree./3, 1.0992, 1.5368. Similarly prepd. was 85.2% II (R = Me, R1 = PhCH2, R2 = CO2Me), b2 161-2.degree., n20D 1.4110, d20 1.5542. Sapon. of II (R1 = H, R2 = CO2Me) with 10% KOH gave the following II (R1 = H, R2 = CO2H) (R, % yield, and m.p. given): p-C1C6H4CH2, 90.3, 98-9.degree.; p-MeOC6H4CH2, 83.4, 124-5.degree.; p-EtOC6H4CH2, 85.3, 148-9.degree.; p-PrOC6H4CH2, 82.3, 111-12.degree.; p-BuOC6H4CH2, 83.5, 125-6.degree.; p-AmOC6H4CH2, 81.4, 117-18.degree.. Similarly prepd. was 90.3% II (R = Me, R1 = PhCH2, R2 = CO2H), m. 134-5.degree.. Decarboxylation of II (R2 = CO2H) carried out at 190-250.degree. gave the following II (R2 = H) (R, R1, % yield, b.p./mm., n20D, and d20 given): p-ClC6H4CH2, H, 93.9, 119-20.degree./3, 1.4482, 1.1189; p-MeOC6H4CH2, H, 81.5, 122-3.degree./2, 1.5484, 1.1065; p-EtOC6H4CH2, H, 90.4, 123-5.degree./2, 1.5400, 1.0683; p-PrOC4H4CH2, H, 92.8, 135-6.degree./2, 1.5330, 1.0519; p-BuOC6H4CH2, H, 94.5, 142-4.degree./2, 1.5278, 1.0355; p-AmOC6H4CH2, H, 90.5, 151-3/2, 1.5238, 1.0239; Me, PhCH2, 89.5, 122-4.degree./15, 1.5415, 0.9871. From disubstituted furan was obtained the 4-benzyl-5-methyl deriv. which also was decarboxylated. The 5- and 4,5-substituted furans were formylated

acetylated. Formylation was accomplished by methods previously described (CA 59: 2763g). To 0.15 mole Me2NCHO at 0.degree., 0.15 mole POCl3 was added slowly with stirring. The mixt. was stirred 30 min. at 0.degree., 0.1 mole freshly distd. 2-ethoxybenzylfuran was added at 10.degree.during

and


0.5 hr., and the mixt. kept in an ice bath 30 min., poured into 200 ml. ice water at room temp., neutralized with Na2CO3, and kept overnight to give the following II (R2 = CHO) (R, R1, % yield, b.p./mm., m.p., n2OD, and d2O given): p-ClC6H4CH2, H, 73.4, 176-8.degree./3, 39-40, -, -; p-MeOC6H4CH2, H, 72.5, 190-2.degree./3, -, 1.5904, 1.1767; p-EtOC6H4CH2, H, 81.5, 186-8.degree./3, -, 1.5768, 1.1930; p-PrOC6H4CH2, H, 79.7, 208-10.degree./3, 37-8.degree., -, -; p-BuOC6H4CH2, H, 81.2, 190-2.degree./3, 42-3.degree., -, -; p-AmOC6H4CH2, H, 80.7, 198-9.degree./3, 44-6.degree., -, -; Me, PhCH2, 87.5, 171-2.degree./5, -, 1.5869, 1.1182. To 0.1 mole freshly distd. 5-(p-ethoxybenzyl) furan and 0.2 mole Ac2O at 0.degree., H3PO4 was added with stirring and the mixt. stirred 30 min. and heated on a boiling water bath 3 hrs. to give the following II (R2 = Ac) (R, R1, % yield, b.p./mm., m.p., n2OD, and d2O given): p-ClC6H4CH2, H, 70.3, 171-2.degree./2, 34-5.degree., -, -; p-MeOC6H4CH2, H, 50.3, 191-2.degree./2, -, 1.5750, 1.1405; p-EtOC6H4CH2, H, 51.8, 175-8.degree./2, -, 1.6502, 1.1283; p-PrOC6H4CH2, H, 63.2, 185-7.degree./2, -, 1.5558, 1.1177; p-BuOC6H4CH2, H, 65.5, 189-90.degree./2, -, 1.5598, 1.0909; p-AmOC6H4CH2, H, 67.1, 193-5.degree./2, 48-50.degree., -, -; Me, PhCH2, 40.7, 163-5.degree./2,

1.5720, 1.1011. The III listed in the first table were obtained by action

of the appropriate pyridinecarboxylic acid hydrazide on the substituted furfural or substituted 2-acetylfuran in an alc. medium. From equimol. amts. of 5-methyl-4-benzylfuran-2-carbonyl chloride and picolinic acid hydrazide in 60 ml. dry pyridine heated at 120.degree. for 10 hrs. were obtained the IV listed in the second table. [TABLE OMITTED] To equimol. amts. of the HCl salt, the chloride, and the hydrazide of picolinic acid, 7 g. KOH in 200 ml. EtOH was added with stirring and the mixt. heated 10

```
hrs. to give the following RCONHNHCOR1 (R, R1, % yield, and m.p. given):
     .alpha.-C5H4N, .alpha.-C5H4N, 37.1, 127-9.degree.; .alpha.-C5H4N,
     .beta.-C5H4N, 35.2, 215-16.degree.; .alpha.-C5H4N, .gamma.-C5H4N, 16.9,
     208-9.degree.; .beta.-C5H4N, .beta.-C5H4N, 25.6, 208-10.degree.;
     .beta.-C5H4N, .gamma.-C5H4N, 20.2, 185-7.degree.; .gamma.-C5H4N, .gamma.-C5H4N, 17.5, 196-8.degree.. [TABLE OMITTED] Tubercular activity
     was tested in vitro. The most active compds. were derivs. of
isonicotinic
     acid pyridinecarboxylic acids.
     15033-03-1P 15033-04-2P 15033-05-3P
IT
     15033-06-4P 15033-07-5P 15033-08-6P
     15033-09-7P 15033-10-0P 15033-11-1P
     RL: SPN (Synthetic preparation); PREP (Preparation)
         (prepn. of)
     15033-03-1 CAPLUS
RN
     Hydrazine, 1-(5-benzyl-2-furoyl)-2-picolinoyl- (8CI) (CA INDEX NAME)
CN
```

RN 15033-04-2 CAPLUS CN Hydrazine, 1-(5-benzyl-2-furoyl)-2-nicotinoyl- (8CI) (CA INDEX NAME)



RN 15033-05-3 CAPLUS

CN Hydrazine, 1-(5-benzyl-2-furoyl)-2-isonicotinoyl- (8CI) (CA INDEX NAME)

RN 15033-06-4 CAPLUS

CN Hydrazine, 1-[5-(p-methylbenzyl)-2-furoyl]-2-picolinoyl- (8CI) (CA INDEX NAME)

$$\begin{array}{c|c} CH_2 & O & O & O \\ C-NH-NH-C & N \end{array}$$

RN 15033-07-5 CAPLUS

CN Hydrazine, 1-[5-(p-methylbenzyl)-2-furoyl]-2-nicotinoyl- (8CI) (CA INDEX NAME)

RN 15033-08-6 CAPLUS

CN Hydrazine, 1-isonicotinoyl-2-[5-(p-methylbenzyl)-2-furoyl]- (8CI) (CA INDEX NAME)

$$\begin{array}{c|c} CH_2 & O & O & O \\ \hline C-NH-NH-C & N \end{array}$$

RN 15033-09-7 CAPLUS
CN Hydrazine, 1-[5-(p-methoxybenzyl)-2-furoyl]-2-picolinoyl- (8CI) (CA INDEX
NAME)

$$\begin{array}{c|c} & & & & & & & & & & & & & & & & \\ & & & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ & & \\$$

RN 15033-10-0 CAPLUS
CN Hydrazine, 1-[5-(p-methoxybenzyl)-2-furoyl]-2-nicotinoyl- (8CI) (CA INDEX
NAME)

=> d his

(FILE 'HOME' ENTERED AT 09:56:50 ON 26 JUN 2002)

FILE 'REGISTRY' ENTERED AT 09:57:03 ON 26 JUN 2002 L1 STRUCTURE UPLOADED

L2 QUE L1 L3 50 S L1 L4 994 S L1 FUL

FILE 'CAPLUS' ENTERED AT 09:58:28 ON 26 JUN 2002

L5 26 S L4

=> d 11

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

## => logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION 115.70 256.57 FULL ESTIMATED COST SINCE FILE TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) ENTRY SESSION CA SUBSCRIBER PRICE -16.11-16.11

STN INTERNATIONAL LOGOFF AT 10:00:59 ON 26 JUN 2002